



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>G01N 33/68, 33/50</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 97/48983</b> (43) International Publication Date: 24 December 1997 (24.12.97)</p>
<p>(21) International Application Number: PCT/US97/10601 (22) International Filing Date: 18 June 1997 (18.06.97) (30) Priority Data: 08/665,649 18 June 1996 (18.06.96) US (71) Applicants (for all designated States except US): ATHENA NEUROSCIENCES, INC. [US/US]; 800 Gateway Boulevard, South San Francisco, CA 94080 (US). BRIGHAM AND WOMEN'S HOSPITAL [US/US]; 75 Francis Street, Boston, MA 02115 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CITRON, Martin [DE/US]; 116 Riverway #8, Boston, MA 02215 (US). SELKOE, Dennis, J. [US/US]; 166 Moss Hill Road, Jamaica Plain, MA 02130 (US). SEUBERT, Peter, A. [US/US]; 222 Northwood Drive, South San Francisco, CA 94080 (US). SCHENK, Dale [US/US]; 1542 Los Altos Drive, Burlingame, CA 94010 (US). (74) Agents: STORELLA, John, R. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: SCREENING COMPOUNDS FOR THE ABILITY TO ALTER THE PRODUCTION OF AMYLOID-<math>\beta</math> PEPTIDE (<math>x \geq 41</math>)</p>		
<p>(57) Abstract</p> <p>This invention provides methods of screening compounds for their ability to alter the production of <math>A\beta</math> (<math>x \geq 41</math>) alone or in combination with <math>A\beta</math> (<math>x \leq 40</math>). The methods involve administering compounds to cells, specifically measuring the amounts of <math>A\beta</math> (<math>x \leq 40</math>) and <math>A\beta</math> (<math>x \geq 41</math>) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AL</b>	Albania	<b>ES</b>	Spain	<b>LS</b>	Lesotho	<b>SI</b>	Slovenia
<b>AM</b>	Armenia	<b>FI</b>	Finland	<b>LT</b>	Lithuania	<b>SK</b>	Slovakia
<b>AT</b>	Austria	<b>FR</b>	France	<b>LU</b>	Luxembourg	<b>SN</b>	Senegal
<b>AU</b>	Australia	<b>GA</b>	Gabon	<b>LV</b>	Latvia	<b>SZ</b>	Swaziland
<b>AZ</b>	Azerbaijan	<b>GB</b>	United Kingdom	<b>MC</b>	Monaco	<b>TD</b>	Chad
<b>BA</b>	Bosnia and Herzegovina	<b>GE</b>	Georgia	<b>MD</b>	Republic of Moldova	<b>TG</b>	Togo
<b>BB</b>	Barbados	<b>GH</b>	Ghana	<b>MG</b>	Madagascar	<b>TJ</b>	Tajikistan
<b>BE</b>	Belgium	<b>GN</b>	Guinea	<b>MK</b>	The former Yugoslav Republic of Macedonia	<b>TM</b>	Turkmenistan
<b>BF</b>	Burkina Faso	<b>GR</b>	Greece	<b>ML</b>	Mali	<b>TR</b>	Turkey
<b>BG</b>	Bulgaria	<b>HU</b>	Hungary	<b>MN</b>	Mongolia	<b>TT</b>	Trinidad and Tobago
<b>BJ</b>	Benin	<b>IE</b>	Ireland	<b>MR</b>	Mauritania	<b>UA</b>	Ukraine
<b>BR</b>	Brazil	<b>IL</b>	Israel	<b>MW</b>	Malawi	<b>UG</b>	Uganda
<b>BY</b>	Belarus	<b>IS</b>	Iceland	<b>MX</b>	Mexico	<b>US</b>	United States of America
<b>CA</b>	Canada	<b>IT</b>	Italy	<b>NE</b>	Niger	<b>UZ</b>	Uzbekistan
<b>CF</b>	Central African Republic	<b>JP</b>	Japan	<b>NL</b>	Netherlands	<b>VN</b>	Viet Nam
<b>CG</b>	Congo	<b>KE</b>	Kenya	<b>NO</b>	Norway	<b>YU</b>	Yugoslavia
<b>CH</b>	Switzerland	<b>KG</b>	Kyrgyzstan	<b>NZ</b>	New Zealand	<b>ZW</b>	Zimbabwe
<b>CI</b>	Côte d'Ivoire	<b>KP</b>	Democratic People's Republic of Korea	<b>PL</b>	Poland		
<b>CM</b>	Cameroon	<b>KR</b>	Republic of Korea	<b>PT</b>	Portugal		
<b>CN</b>	China	<b>KZ</b>	Kazakstan	<b>RO</b>	Romania		
<b>CU</b>	Cuba	<b>LC</b>	Saint Lucia	<b>RU</b>	Russian Federation		
<b>CZ</b>	Czech Republic	<b>LI</b>	Liechtenstein	<b>SD</b>	Sudan		
<b>DE</b>	Germany	<b>LK</b>	Sri Lanka	<b>SE</b>	Sweden		
<b>DK</b>	Denmark	<b>LR</b>	Liberia	<b>SG</b>	Singapore		
<b>EE</b>	Estonia						

5 SCREENING COMPOUNDS FOR THE ABILITY TO ALTER THE PRODUCTION OF  
AMYLOID- $\beta$  PEPTIDE (x- $\geq$ 41)

10 This invention was made in part with Government  
support under grant no. 2 P50 AG05134 awarded by the National  
Institutes of Health. The Government may have rights in this  
invention.

15 **BACKGROUND OF THE INVENTION**

1. **Field of the Invention**

The present invention relates generally to neurology  
and, more particularly, to assays, such as immunoassays, for  
screening for compounds that specifically alter the production  
20 of various isoforms of A $\beta$ .

Alzheimer's disease (AD) is a degenerative brain  
disorder characterized clinically by progressive loss of  
memory, cognition, reasoning, judgment and emotional stability  
that gradually leads to profound mental deterioration and  
25 ultimately death. AD is a very common cause of progressive  
mental failure (dementia) in aged humans and is believed to  
represent the fourth most common medical cause of death in the  
United States. AD has been observed in all races and ethnic  
groups worldwide and presents a major present and future public  
30 health problem. The disease is currently estimated to affect  
about two to three million individuals in the United States  
alone. AD is at present incurable. No treatment that  
effectively prevents AD or reverses its symptoms or course is  
currently known.

35 The brains of individuals with AD exhibit  
characteristic lesions termed senile plaques and  
neurofibrillary tangles. Large numbers of these lesions are  
generally found in patients with AD in several areas of the  
human brain important for memory and cognitive function.

Smaller numbers of these lesions in a more restricted anatomical distribution are sometimes found in the brains of aged humans who do not have clinical AD. Senile plaques and vascular amyloid deposits (amyloid angiopathy) also  
5 characterize the brains of individuals beyond a certain age with Trisomy 21 (Down's Syndrome) and Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D). The principal chemical constituent of the senile plaques and  
10 vascular amyloid deposits characteristic of AD and the other disorders mentioned above is a protein designated the amyloid- $\beta$  peptide ( $A\beta$ ) or sometimes  $\beta$ AP,  $A\beta$ P or  $\beta$ /A4.  $A\beta$  was first purified and a partial amino acid sequence reported in Glenner and Wong (1984) *Biochem. Biophys. Res. Commun.* 120:885-890. The isolation procedure and the sequence data for the first 28  
15 amino acids are described in U.S. Patent No. 4,666,829. Forms of  $A\beta$  having amino acids beyond number 40 were first reported by Kang et al. (1987) *Nature* 325:733-736.

Roher et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:10836-840 showed that  $A\beta(1-42)$  is the major constituent in  
20 neuritic plaques, including significant amounts of isomerized and racemized aspartyl residues as their  $NH_2$ -termini. The authors also reported that  $A\beta(17-42)$  ( $p3(42)$ ) predominates in diffuse (early) plaques, whereas  $A\beta(1-40)$  is the major constituent in the meningeal vessel deposits, comprising 60% of  
25 the total  $A\beta$  in those vessels. Iwatsubo et al. (1994) *Neuron* 13:45-53 showed that  $A\beta_{42(43)}$ -containing senile plaques are the major species of senile plaques in sporadic AD brains. Iwatsubo et al. (1995) *Annals of Neurology* 37:294-299 and Lemere et al. (1996) *Neurobiology of Disease* 3:16-32 reported  
30 that  $A\beta_{42(43)}$  is the major constituent of senile plaques in Down's syndrome brains and is the initially deposited  $A\beta$  species in the development of AD-type neuropathological lesions in these patients. In addition, Gravina et al., (1995) *J. Biol. Chem.* 270:7013-7016 reported both biochemical and  
35 immunocytochemical evidence that  $A\beta_{42(43)}$  peptides were the most abundant constituents of senile plaques in AD brains and exceeded the amounts of  $A\beta_{40}$  peptides in such plaques.

Molecular biological and protein chemical analyses conducted during the last several years have shown that A $\beta$  is a small fragment of a much larger precursor protein, referred to as the  $\beta$ -amyloid precursor protein (APP), that is normally produced by cells in many tissues of various animals, including humans. Knowledge of the structure of the gene encoding APP has demonstrated that A $\beta$  arises as a peptide fragment that is cleaved from the carboxy-terminal end of APP by as-yet-unknown enzymes (proteases). The precise biochemical mechanism by which the A $\beta$  fragment is cleaved from APP and subsequently deposited as amyloid plaques in the cerebral tissue and in the walls of cerebral and meningeal blood vessels is currently unknown. Importantly, Haass et al. (*Nature* 359:322-325) and Seubert et al. ((1992) *Nature* 359:325-327) discovered that essentially all cells expressing the APP gene normally secrete an array of A $\beta$  peptides, and these peptides can readily be detected and assayed in cell culture fluid (conditioned media) and human biological fluids such as plasma and cerebrospinal fluid. It has subsequently been shown that these fluids contain both the more abundant A $\beta$ 40-ending peptides and the less abundant A $\beta$ 42(43)-ending peptides (Dovey et al. (1993) *Neuroreport* 4:1039-1042 and Vigo-Pelfrey et al. (1993) *J. Neurochem.* 61:1965-68)

Several lines of evidence indicate that progressive cerebral deposition of A $\beta$  plays a seminal role in the pathogenesis of AD and can precede cognitive symptoms by years or decades (for review, see Schenk (1995) *J. Med. Chem.* 38:4141-4154, Selkoe (1994) *J. Neuropath. and Exp. Neurol.* 53:438-447 and Selkoe (1991) *Neuron* 6:487). One of the most important lines of evidence is the discovery in 1991 that missense DNA mutations in the APP gene at amino acid 717 of the 770-amino acid isoform of APP can be found in affected members but not unaffected members of several families with a genetically determined (familial) form of AD (Goate et al. (1991) *Nature* 349:704-706; Chartier Harlan et al. (1991) *Nature* 353:844-846; and Murrell et al. (1991) *Science* 254:97-99). Suzuki et al. (1994) "An increased percentage of long amyloid  $\beta$ -protein secreted by familial amyloid  $\beta$ -protein precursor

( $\beta$ APP717) mutants," *Science* 264:1336-1340 subsequently showed that, compared to normal individuals, the 717 mutation causes a higher relative production of the  $A\beta(1-42)$  peptide. In addition, a double mutation changing lysine<sup>670</sup>-methionine<sup>671</sup> to asparagine<sup>670</sup>-leucine<sup>671</sup> (with reference to the 770 isoform of APP) was reported in a Swedish family with familial AD in 1992 (Mullan et al. (1992) *Nature Genet* 1:345-347) and is referred to as the Swedish APP variant.

Genetic linkage analyses have demonstrated that the aforementioned mutations are the specific molecular cause of AD in the members of such families that carry these mutant APP genes. In addition, a mutation at amino acid 693 of the 770-amino acid isoform of APP has been identified as the cause of the  $A\beta$  deposition disease, Hereditary Cerebral Hemorrhage With Amyloidosis Dutch type (HCHWA-D), and a mutation from alanine to glycine at amino acid 692 appears to cause the phenotype of AD in some family members and the phenotype of HCHWA-D in others. The discovery of these APP mutations in genetically based cases of AD argues that genetic alteration of APP and subsequent deposition of its  $A\beta$  fragment can cause AD.

Recently, evidence has accumulated suggesting that  $A\beta(42)$  plays the key role in the process of senile plaque formation in AD. First, *in vitro* data demonstrate that  $A\beta(42)$  accelerates the formation of  $A\beta$  fibrils (and thus senile plaques) by a nucleation dependent mechanism (Jarrett et al. (1993) *Biochemistry* 32:4693-4697). Second, while accounting for  $\leq 10\%$  of total  $A\beta$  secreted from cells (roughly 90% is  $A\beta(40)$  (Dovey et al. (1993) *Neuroreport* 4:1039-1042; Asami-Odaka et al. (1995) "Long amyloid  $\beta$ -protein secreted from wild-type human neuroblastoma IMR-32 cells." *Biochemistry* 34:10272-10278),  $A\beta(42)$  is the major plaque component (Kang et al. (1987) *Nature* 325:733-736; Iwatsubo et al. (1994) *Neuron* 13:45-53; Iwatsubo et al. (1995) *Ann. Neurol.* 37:294-299; Gravina et al. (1995) *J. Biol. Chem.* 270:7013-7016; Lemere et al. (1996) *Neurobiology of Disease* 3:16-32). Furthermore, all 3 early onset familial AD genes identified to date have been shown to lead to an increase in cellular secretion of  $A\beta(42)$ . Only the Swedish APP missense mutation increases the secretion of both

A $\beta$ (40) and A $\beta$ (42) peptides (Dovey et al. (1993) *Neuroreport* 4:1039-1042, whereas the APP717 mutations and the presenilin mutations appear not to increase A $\beta$ (40) peptides (Suzuki et al. (1994) *Science* 264:1336-1340; Scheuner et al. (1995) *Neurosci. Abstracts* in press). Thus, the longer A $\beta$ (42) peptide appears to be a prime target for therapeutic intervention. However, none of the proteases involved in the major steps of APP processing have been definitively identified, including  $\gamma$ -secretase, the protease which generates the C-terminus of A $\beta$ .

10 It has generally been assumed that the same protease(s) generate both A $\beta$ (40) and A $\beta$ (42) and it has been shown that both forms share a common secretory mechanism which involves acidic intracellular compartments such as the late Golgi or early endosomes (Koo and Squazzo (1994) *J. Biol. Chem.* 269:17386-17389; Asami-Odaka et al. (1995) *Biochemistry* 34:10272-10278). Recently, Higaki et al. ((1995) *Neuron*, 14:651-659) have shown that the Calpain inhibitor, MDL 28170, inhibits the production of both total A $\beta$  and total p3 and leads to an accumulation of their respective 12 kDa and 10 kDa APP precursor fragments in

20 treated cells. These data suggest that the compound directly inhibits at least some form of  $\gamma$ -secretase although no data are provided as to what specific form of A $\beta$  and p3 are affected.

Despite the progress which has been made in understanding the underlying mechanisms of AD, there remains a need for assays to identify candidate compounds for preventing or treating the disease.

25

#### SUMMARY OF THE INVENTION

According to current theory, the processing of APP is

30 believed to involve several specific cleavages by proteases. The enzyme that cleaves APP between amino acids 671/672 (referring to the  $\beta$ APP<sub>770</sub> isoform) is called  $\beta$ -secretase. The enzyme that cleaves between amino acids 687/688 of APP (16/17 of A $\beta$ ) is called  $\alpha$ -secretase. Until now it was believed that

35 cleavage of APP that yielded A $\beta$ (40) and A $\beta$ (42) was carried out by a single enzyme called  $\gamma$ -secretase. However, we have discovered that a compound can inhibit the production of A $\beta$ (40) but not A $\beta$ (42). In particular, we have discovered that

compounds, thought to inhibit the production  $A\beta$  in general, actually inhibit production of  $A\beta(40)$  but not  $A\beta(42)$ . This indicates that multiple  $\gamma$ -secretase mechanisms are at work which can be pharmacologically dissociated.

5           Because  $A\beta(42)$  is the major component of  $\beta$ -amyloid plaques and initiates amyloid plaque formation in AD patients, it is important to have tools to screen compounds to identify those that specifically inhibit the production of  $A\beta(42)$  and  $A\beta(40)$ , either simultaneously or separately. The current  
10 invention provides such assays.

          This invention provides methods for determining whether a compound alters the amount of at least one  $A\beta(x-\geq 41)$  peptide produced by a cell. The methods involve administering the compound to a culture comprising the cell; measuring the  
15 amount of the  $A\beta(x-\geq 41)$  peptide, specifically, in a sample from the culture; and determining whether the measured amount is different than the amount expected in a sample from a culture comprising the cell to which no compound has been administered. A difference between the measured amount and the expected  
20 amount indicates that the compound alters the amount of an  $A\beta(x-\geq 41)$  peptide produced by the cell.

          In another aspect, this invention provides methods for determining whether a compound alters the amount of at least one  $A\beta(x-\geq 41)$  peptide produced by a cell and alters the  
25 amount of either total  $A\beta$  or at least one  $A\beta(x-\leq 40)$  peptide produced by the cell. The methods involve administering the compound to a culture comprising the cell; measuring the amount of the  $A\beta(x-\geq 41)$  peptide, specifically, in a sample from the culture; measuring the amount of total  $A\beta$  or the  $A\beta(x-\leq 40)$   
30 peptide, specifically, in a sample from the culture; and determining whether the measured amounts are different than the amounts expected in a sample from a culture comprising the cell to which no compound has been administered. Differences between the measured amounts and the expected amounts indicate  
35 that the compound alters the amount of the  $A\beta(x-\geq 41)$  peptide by a cell and/or the amount of total  $A\beta$  or the  $A\beta(x-\leq 40)$  peptide by the cell.

In one embodiment, the amount of the A $\beta$  peptides are measured by immunoassay and, in particular, sandwich immunoassay comprising capture binding substances bound to a solid phase and a labeled detection binding substance.

5 In sandwich assays for determining the amount of at least one A $\beta$ (x- $\geq$ 41) peptide, the capture antibody preferably is specific for A $\beta$ (x- $\geq$ 41) peptides, e.g., raised against peptide NH<sub>2</sub>-Cys-NH-CH<sub>2</sub>-(CH<sub>2</sub>)<sub>5</sub>-CO-GLMVGGVVIA-COOH (SEQ ID NO:4). The detection binding substance in this assay can be an antibody  
10 specific for A $\beta$  peptides whose amino-terminal amino acid is no. 1 of A $\beta$ , or can be specific for an epitope within the junction region of A $\beta$ . In another embodiment the capture binding substance for measuring the amount of at least one of A $\beta$ (x- $\geq$ 41) peptide is specific for an epitope within the junction region  
15 of A $\beta$  and the detection binding substance is an antibody specific for A $\beta$ (x- $\geq$ 41).

In sandwich assays for determining the amount of at least one A $\beta$ (x- $\leq$ 40) peptide, the capture binding substance preferably is an antibody specific for A $\beta$ (x- $\leq$ 40) peptides,  
20 e.g., raised against the peptide NH<sub>2</sub>-Cys-NH-CH<sub>2</sub>-(CH<sub>2</sub>)<sub>5</sub>-CO-GLMVGGVV-COOH (SEQ ID NO:5). The labeled detection binding substance can be an antibody specific for the A $\beta$  peptides whose amino-terminal amino acid is no. 1 of A $\beta$  or an antibody specific for an epitope within the junction region of A $\beta$ . In  
25 another embodiment the capture binding substance for measuring the amount of at least one of A $\beta$ (x- $\leq$ 40) peptide is specific for an epitope within the junction region of A $\beta$  and the detection binding substance is an antibody specific for A $\beta$ (x- $\leq$ 40).

In sandwich assays for determining the amount of  
30 total A $\beta$ , the capture binding substance preferably is an antibody specific for an epitope within the junction region of A $\beta$ . The detection binding substance preferably is specific for A $\beta$  peptides whose amino-terminal amino acid is no. 1 of A $\beta$ .

In another embodiment of an immunoassay, the step of  
35 measuring the amount of the A $\beta$ (x- $\geq$ 41) peptide, total A $\beta$  or the A $\beta$ (x- $\leq$ 40) peptide in a sample from the culture comprises: pulsing the culture with a radioactive label for protein; chasing the culture without a radioactive label; administering

the compound to the cell during the chase period; contacting a sample from the culture with a binding substance specific for  $A\beta(x-\geq 41)$  peptides; contacting a sample from the culture with a binding substance specific for total  $A\beta$  or  $A\beta(x-\leq 40)$  peptide; and determining the amount of radioactive label attached to the binding substances.

In other embodiments of the methods the culture comprises primary human neurons, primary neurons from a transgenic PDAPP mouse (i.e., a transgenic mouse whose cells harbor a PDAPP construct), a 293 human kidney cell line, a human neuroglioma cell line, a human HeLa cell line, a primary endothelial cell line, a primary human fibroblast line, a primary lymphoblast line, human mixed brain cells, or a Chinese hamster ovary (CHO) cell line. In one embodiment the cell is a host cell transfected with a recombinant expression vector encoding a human APP, e.g., a Hardy mutation such as V717F or the Swedish mutant; causing the cell to overproduce  $A\beta(x-\geq 41)$  peptides. In another aspect, the methods further comprise the step of determining whether the compound is toxic to the cell.

In another aspect this invention provides kits for specifically detecting at least one  $A\beta(x-\geq 41)$  peptide and at least one  $A\beta(x-\leq 40)$  peptide in a sample. The kits include a binding substance specific for  $A\beta(x-\geq 41)$  peptides; and a binding substance specific for  $A\beta(x-\leq 40)$  peptides.

In another aspect this invention provides kits for specifically detecting at least one  $A\beta(x-\geq 41)$  peptide and either total  $A\beta$  or at least one  $A\beta(x-\leq 40)$  peptide in a sample in a sandwich immunoassay. The kits include at least two different binding substances for measuring the amount of  $A\beta(x-\geq 41)$  peptide; and at least two different binding substances for measuring the amount of total  $A\beta$  or  $A\beta(x-\leq 40)$  peptides.

In another aspect this invention provides methods for determining whether a compound alters the amount of at least one  $A\beta(x-\geq 41)$  peptide produced by a non-human mammal and alters the amount of either total  $A\beta$  or at least one  $A\beta(x-\leq 40)$  peptide produced in the non-human mammal. The methods involve measuring a first amount of the  $A\beta(x-\geq 41)$  peptide in a sample from a non-human animal used as a model of Alzheimer's disease;

measuring a first amount of total A $\beta$  or the A $\beta$ (x- $\leq$ 40) peptide in a sample from the non-human animal; administering the compound to the non-human animal; measuring a second amount of the A $\beta$ (x- $\geq$ 41) peptide in a sample from the non-human animal; 5 measuring a second amount of total A $\beta$  or the A $\beta$ (x- $\leq$ 40) peptide in a sample from the non-human animal; and comparing the first amounts with the second amounts. The comparison indicates whether the compound increases, decreases, or leaves unchanged the amount of the A $\beta$ (x- $\geq$ 41) peptide and increases, decreases, 10 or leaves unchanged the amount of the A $\beta$ (x- $\leq$ 40) peptide. In certain embodiments the non-human animal is a rodent, in particular, a mouse. The non-human animal can harbor a copy of an expressible transgene sequence which encodes a Hardy mutation (e.g., V717F) or the Swedish mutation of human  $\beta$ - 15 amyloid precursor protein (APP).

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1. Shows standard curves of A $\beta$ (1-40) and A $\beta$ (1-42) with 2G3 as a capture antibody.

20 Fig. 2. Shows standard curves of A $\beta$ (1-40) and A $\beta$ (1-42) with 21F12 as a capture antibody.

Fig. 3. Shows that compound MDL 28170 influences  $\beta$ APP metabolism. (0) untreated K695sw cells; (200) K695sw cells treated with 200  $\mu$ M MDL 28170 during the chase period. 25 Lanes 1,2: aliquot of total chase media run directly on the gel. Lanes 3,4: antibody 1736 immunoprecipitation of chase media. Lanes 5,6: antibody 192sw immunoprecipitation of chase media. Note that  $\beta$ -cut APPs (lanes 5,6) runs slightly below  $\alpha$ -cut APPs (lanes 3,4), as expected. Lanes 7,8: antibody C7 30 immunoprecipitation of cell lysates. Lanes 9,10: antibody 1282 immunoprecipitation of cell lysates.

Figs. 4A-4B. Differential inhibition of A $\beta$ (42) and A $\beta$ (40) formation. (A) Labeled K695sw cells were chased with the indicated concentrations of MDL 28170, and the chase media 35 were precipitated with 21F12 (upper panel) followed by antibody 1282 (lower panel). (B) Quantitation of the effect of 200  $\mu$ M MDL 28170 on A $\beta$  and p3 in the chase media by phosphorimaging. The bars show the relative pixel number compared to an

untreated control (set at 100%). The decreases in  $A\beta_{total}$  and  $p3_{total}$  relative to an untreated control were significant (\*) (two-tailed t-test,  $n=4$ ,  $p<0.001$ ), whereas the decreases in  $A\beta(42)$  and  $p3(42)$  upon treatment with MDL 28170 did not reach  
5 significance. The difference in reduction of  $A\beta(42)$  level vs. total  $A\beta$  level is significant (two-tailed t-test,  $n=4$ ,  $p<0.01$ ). The difference in inhibition of  $p3(42)$  vs. total  $p3$  is also significant (two-tailed t-test,  $n=4$ ,  $p<0.05$ ).

Figs. 5A-5F. Differential inhibition of  $A\beta$   
10 production by K695sw cells under a variety of conditions. (A) treatment with 1  $\mu$ M PDBu (P) decreases both  $A\beta(42)$  and  $A\beta_{total}$ . Upper panel: antibody 21F12 precipitation, lower panel: subsequent antibody 1282 precipitation. (B-E) K695sw cells were chased with (M) or without (0) 200  $\mu$ M MDL 28170, and the  
15 chase media were immunoprecipitated (B) first with antibody BC05 (upper panel) and then with antibody 1282 (lower panel); (C) first with antibody C42 (upper panel) and then with antibody 1282 (lower panel); (D) first with antibody 2G3 (upper panel) and then with antibody 21F12 (lower panel); (E) after  
20 splitting the medium into two aliquots, either with antibody 21F12 (upper panel) or antibody 1282 (lower panel). (F) cells were labeled for 3 h in the presence of 100  $\mu$ M MDL 28170, and the medium was immunoprecipitated first with antibody 21F12 (upper panel) and then with antibody 1282 (lower panel).

25 Figs. 6A-6C. Differential inhibition of  $A\beta$  production in different cell types.  $^{35}S$ -methionine labeled cells were chased with the indicated concentrations of MDL 28170 and precipitated with antibody 21F12 (upper panel) followed by antibody 1282 (lower panel). (A) V717F cells. The  
30 relatively low APP expression leads to a faint  $A\beta(42)$  band. (B) CHO695 cells. Note that in CHO cells the  $p3$  bands migrate as doublets, as described (Koo and Squazzo, (1994) "Evidence that production and release of amyloid  $\beta$ -protein involves the endocytic pathway." *J. Biol. Chem.* 269:17386-17389). (C)  
35 SKN695 cells. While  $A\beta(42)$  and  $p3(42)$  are slightly increased at 200  $\mu$ M MDL 28170,  $A\beta_{total}$  and  $p3_{total}$  are decreased.

Fig. 7. Shows a summary sketch of some of the known proteolytic processing pathways of APP.

Fig. 8A. Shows a schematic of a combination cDNA/genomic coding sequence allowing alternative splicing of the KPI and OX-2 exons.

Fig. 8B. Shows a schematic of a combination cDNA/genomic coding sequence bearing a mutation at position 717 and allowing alternative splicing of the KPI and OX-2 exons.

Fig. 9. Diagram of the intermediate constructs used to construct the APP splicing cassette and the PDAPP vector.

Fig. 10A-D. The DNA sequence (SEQ ID NO:2) and the deduced amino acid sequence (SEQ ID NO:3) of APP770.

Fig. 11. Diagram of the genomic region of APP present in the PDAPP construct. The sizes of original introns 6, 7 and 8, as well as the sizes of the final introns are indicated in the diagram. The locations of the deletions in introns 6 and 8 present in the PDAPP construct also are indicated.

Fig. 12. Schematic map of the PDAPP vector, a combination cDNA/genomic APP construct.

Figs. 13A-13O depict the percent inhibition of  $A\beta$  by several compounds using the brain cell culture method described in Example VIII. The charts show inhibition of total  $A\beta$  ("%  $A\beta$  inhibition"), inhibition of  $A\beta(42)$  ("% 1-42 inhibition") and inhibition of the metabolism of MTT ("% MTT inhibition") (greater inhibition indicates greater cytotoxicity).

## DETAILED DESCRIPTION OF THE INVENTION

### I. DEFINITIONS

The term "binding substance" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, which specifically bind and recognize an analyte (antigen). The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Antibodies exist, e.g., as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases. This includes, e.g., Fab' and F(ab)', fragments. The term "binding substance," as used herein, also includes

antibody fragments either produced by the modification of whole antibodies or those synthesized *de novo* using recombinant DNA methodologies.

The term "immunoassay" is an assay that utilizes a binding substance to specifically bind an analyte. The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the analyte.

A binding substance "specifically binds to" or "is specifically immunoreactive with" a protein when the binding substance functions in a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified binding substances bind preferentially to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. A variety of immunoassay formats may be used to select binding substances specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

A "label" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include  $^{32}\text{P}$ , fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, dioxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available. Binding substances can be made detectable, e.g., by incorporating a radio-label into the peptide, and used to detect antibodies specifically reactive with the peptide. A label often generates a measurable signal, such as

radioactivity, fluorescent light or enzyme activity, which can be used to quantitate the amount of bound label.

## II. IN VITRO SCREENING

5 Alzheimer's disease is characterized by the initial deposition of  $A\beta(x-\geq 41)$  in the form of amyloid plaques in the brain. Therefore, effective treatments for AD are expected to decrease the production of these peptides, whereas agents that hasten progress of the disease are expected to increase  
10 production of the peptide. Prior screening methods looked for compounds that decreased total  $A\beta$ . However, since  $A\beta(x-\geq 41)$  peptides are a small fraction of total  $A\beta$ , those assays could not determine whether the compound specifically inhibited  $A\beta(x-\geq 41)$  peptides. As results described herein indicate, compounds  
15 can alter the production of  $A\beta(x-\leq 40)$  but not  $A\beta(x-\geq 41)$ . Because  $A\beta(42)$  is the major constituent of neuritic plaques, it is useful to identify compounds that specifically inhibit the production of  $A\beta(x-\geq 41)$  peptides, either in addition to, or instead of  $A\beta(x-\leq 40)$  peptides. Accordingly, this invention  
20 provides methods for screening compounds that specifically elevate or decrease the production of the amount of  $A\beta(x-\geq 41)$  by a cell and compounds that elevate or decrease production of both  $A\beta(x-\geq 41)$  and  $A\beta(x-\leq 40)$  (e.g., total  $A\beta$ ), or of one or the other of these peptides. Compounds that decrease production of  
25  $A\beta(x-\geq 41)$  are candidates for use in treating the disease, while compounds that increase its production may hasten the disease and are to be avoided by humans.

Screening methods of this invention for determining whether a test compound specifically alters the amount of  $A\beta(x-\geq 41)$  produced by a cell involve administering the compound to  
30 the cell, usually in culture, measuring the amount of  $A\beta(x-\geq 41)$  specifically produced by the cell, and determining whether this amount is greater than, less than or the same as an amount the cell is expected to produce in the absence of the compound. If  
35 the amounts are different, then the compound affects the production of  $A\beta(x-\geq 41)$  by the cell. This amount can be measured, for example, in a sample from the culture, such as

medium conditioned by the cell in culture, or in extracts derived from cells harvested from the culture.

The expected amount generally will be a control amount determined by measuring  $A\beta(x-\geq 41)$  produced by the cell in the absence of the compound. However, one also may determine the expected amount by extrapolation; measuring the amount of  $A\beta(x-\geq 41)$  produced upon administration of different amounts of the compound to the cell, and using these figures to calculate the expected amount. In certain instances measuring a control amount for the purposes of comparison may not be necessary because the effect of the compound on  $A\beta(x-\geq 41)$  production is clear. For example, a compound may render  $A\beta(x-\geq 41)$  undetectable in a cell that normally produces detectable amounts, indicating that the compound decreases  $A\beta(x-\geq 41)$  production from the amount expected in its absence.

In another aspect, this invention provides screening methods for determining whether a compound alters the production of  $A\beta(x-\geq 41)$  by a cell to a different degree than it alters the production of total  $A\beta$  or  $A\beta(x-\leq 40)$  by the cell. These methods are useful for determining whether a compound alters the production of  $A\beta(x-\geq 41)$  in addition to total  $A\beta$ , or alters the production of one or the other of  $A\beta(x-\geq 41)$  and  $A\beta(x-\leq 40)$ . The methods involve administering the compound to the cell (usually in culture). Then, the degree to which the compound alters the production of  $A\beta(x-\geq 41)$ , specifically, by the cell is determined. The degree to which the compound alters the production of total  $A\beta$  or  $A\beta(x-\leq 40)$  by the cell also is determined. Then, the degrees are compared. The comparison indicates whether the compound alters the production of  $A\beta(x-\geq 41)$  instead of or in addition to  $A\beta(x-\leq 40)$ .

Determining the degree to which a compound alters the production of one or the other peptide generally involves measuring the specific amount of the peptide in a sample from the culture; and comparing it with the amounts expected in a sample from a culture comprising the cell to which no compound has been administered.

### III. AMYLOID- $\beta$ PEPTIDE AND RELATED PROTEINS AND PEPTIDES

Various cellular processing pathways for APP are presented in Fig. 7. The terms "amyloid- $\beta$  peptide," "A $\beta$ " or " $\beta$ AP" as used herein refer to an approximately 4.2 kD protein which, in the brains of AD, Down's Syndrome, HCHWA-D and some normal aged subjects, forms the subunit of the amyloid filaments comprising the senile (amyloid) plaques and the amyloid deposits in small cerebral and meningeal blood vessels (amyloid angiopathy). A $\beta$  can occur in a filamentous polymeric form (in this form, it exhibits the Congo-red and thioflavin-S dye-binding characteristics of amyloid described in connection therewith). A $\beta$  can also occur in a non-filamentous form ("preamyloid" or "amorphous" or "diffuse" deposits) in brain tissue, in which form no birefringent staining by Congo red occurs. A portion of this protein in the insoluble form obtained from meningeal blood vessels is described in U.S. Patent No. 4,666,829.

A $\beta$  is an approximately 39-43 amino acid fragment of a large membrane-spanning glycoprotein, referred to as the  $\beta$ -amyloid precursor protein (APP), encoded by a gene on the long arm of human chromosome 21. Forms of A $\beta$  longer than 43 amino acids are also contemplated herein. A $\beta$  is further characterized by its relative mobility in SDS-polyacrylamide gel electrophoresis or in high performance liquid chromatography (HPLC). A sequence for a 43-amino acid-version of A $\beta$  is:

1  
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr

30 11  
Glu Val His His Gln Lys Leu Val Phe Phe

21  
Ala Glu Asp Val Gly Ser Asn Lys Gly Ala

35 31  
Ile Ile Gly Leu Met Val Gly Gly Val Val

41  
40 Ile Ala Thr (SEQ ID NO:1).

As used herein, A $\beta$  also refers to related polymorphic forms of A $\beta$ , including those that result from mutations in the A $\beta$  region of the APP gene.

The term "A $\beta$  fragment" as used herein refers to fragments and degradation products of A $\beta$  which are generated at low concentrations by mammalian cells. Particular A $\beta$  fragments have a molecular weight of approximately 3 kD and are presently  
5 believed to include peptides with, for example, amino acid residues 3-34, 6-27, 6-34, 6-35, 6-42, 11-34, 11-40, 11-43, 12-43, 17-40 and 17-42 of A $\beta$  (Vigo-Pelfrey et al. (1993) *J. Neurochem.* 61:1965-1968).

As used herein, the term "A $\beta$ (x- $\geq$ 41)" refers to A $\beta$  or  
10 an A $\beta$  fragment whose amino-terminus begins at amino acid number 1 of A $\beta$  or thereafter (i.e., which is amino-terminally truncated), and whose carboxy-terminus extends beyond amino acid number 40. These peptides and fragments comprise a heterogenous group. For example, A $\beta$ (6-42), A $\beta$ (11-43) and  
15 A $\beta$ (12-43) all have been found in the CSF. However, this list is not meant to be exclusive. Other peptides from among the group are presumed to exist in the culture media of cells expressing APP and are detectable with the methods described herein. As used herein the term "A $\beta$ (42)" refers to A $\beta$  or an A $\beta$   
20 fragment whose C-terminal amino acid is # 42 of A $\beta$ .

As used herein, the term "A $\beta$ (x- $\leq$ 40)" refers to A $\beta$  or an A $\beta$  fragment whose amino-terminus begins at amino acid number 1 of A $\beta$  or which is amino-terminally truncated, and whose carboxy-terminus extends no further than amino acid number 40.  
25 These peptides and fragments also comprise a heterogenous group. The term "A $\beta$ (40)" refers to A $\beta$  or an A $\beta$  fragment whose C-terminal amino acid is # 40 of A $\beta$ .

As used herein, the term "p3" refers to a peptide whose amino acid sequence is substantially similar to A $\beta$ , but  
30 whose amino-terminal amino acid begins at amino acid 17 of A $\beta$ . The term "p3 fragment" as used herein refers to fragments and degradation products of p3. Whereas p3 is produced through a different processing pathway than A $\beta$ , for the purposes of the detection methods of this invention, p3 and p3 fragments are  
35 considered to be a subset of A $\beta$  peptides, because certain detection techniques that recognize A $\beta$  solely from the carboxy-terminus generally also will recognize p3. Also it is shown

that the same apparent mechanisms generate the p3 and A $\beta$  carboxy-termini.

The term "A $\beta$  junction region" as used herein refers to a region of A $\beta$  which is centered at the site between amino acid residues 16 and 17 (Lys<sup>16</sup> and Leu<sup>17</sup>), which is a principal target for proteolytic processing of APP. Such processing, referred to as " $\alpha$ -secretory" processing, results in a variety of APP fragments which may, for example, terminate at amino acid 16 of A $\beta$  and which, therefore, are potentially immunologically cross-reactive with antibodies to the intact A $\beta$  molecule which are to be used in the methods of the present invention. Antibodies raised against a synthetic peptide including amino acid residues 13-28 have been found to display the requisite specificity for the junction region.

The term "amyloid- $\beta$  precursor protein" (APP) as used herein is defined as a polypeptide that is encoded by a gene of the same name localized in humans on the long arm of chromosome 21 and that includes the A $\beta$  region within the carboxyl third of its coding region. APP is a glycosylated, single-membrane-spanning protein expressed in a wide variety of cells in many mammalian tissues. Examples of specific isotypes of APP which are currently known to exist in humans are the 695-amino acid polypeptide described by Kang et al. (1987) *Nature* 325:733-736; the 751-amino acid polypeptide described by Ponte et al. (1988) *Nature* 331:525-527 (1988) and Tanzi et al. (1988) *Nature* 331:528-530; and the 770-amino acid polypeptide described by Kitaguchi et al. (1988) *Nature* 331:530-532. Examples of specific variants of APP include point mutations which can differ in both position and resultant neuropathological phenotype (for review of known variant mutations see Hardy (1992) *Nature Genet.* 1:233-234).

The term "A $\beta$ -related condition" as used herein is defined as including Alzheimer's disease (which includes familial Alzheimer's disease), Down's Syndrome, HCHWA-D, and advanced aging of the brain.

IV. CELLS EXPRESSING A $\beta$ (x- $\geq$ 41)

Because it is a therapeutic goal to discover compounds that inhibit the production of A $\beta$ (x- $\geq$ 41), the test cells used in the methods of this invention generally are ones  
5 that are able to secrete A $\beta$ (x- $\geq$ 41).

In vitro monitoring of A $\beta$ (x- $\geq$ 41) levels in conditioned medium from a suitable cell culture may be used for drug screening. By growing cells under conditions which result in the secretion of A $\beta$ (x- $\geq$ 41) into the culture medium, and  
10 exposing the cells to test compounds, the effect of these test compounds on A $\beta$ (x- $\geq$ 41) secretion can be observed.

Suitable cell lines include human and animal cell lines, such as, preferably, primary human neurons, and primary neurons from transgenic mice harboring human APP genes, e.g.,  
15 cells from a transgenic PDAPP animal (e.g., mouse), as well as a 293 human kidney cell line, a human neuroglioma cell line, a human HeLa cell line, a primary endothelial cell line (e.g., HUVEC cells), a primary human fibroblast line or a primary lymphoblast line (including endogenous cells derived from  
20 patients with APP mutations), a primary human mixed brain cell culture (including neurons, astrocytes and neuroglia), or a Chinese hamster ovary (CHO) cell line. Particularly useful are cells stably transfected with APP<sub>695</sub> carrying the mutation V717I (valine to isoleucine at position 717 in the APP770 numbering  
25 system). Cell lines which preferentially increase the levels or ratios of A $\beta$ (x- $\geq$ 41) would be particularly useful in the methods of invention. Useful mutants at position 717 (the Hardy mutation) include V717F, V717I or V717G.

Preferred for use in drug screening methods according  
30 to the present invention are cell lines capable of expressing APP variants which overproduce A $\beta$ . By "overproduce," it is meant that the amount of A $\beta$  produced from the variant APP will be at least about one-and-a-half times and preferably at least two or five times greater than the amount produced from any or  
35 all of the normal APP isoforms, e.g., the 695, 751, and 770 amino acid isoforms which have been previously described. Particularly preferred are APP variants having one or several amino acid substitutions directly amino-terminal of the A $\beta$

cleavage site. For example, K293 cells which express an APP<sub>695</sub> DNA bearing a double mutation (Lys<sup>595</sup>->Asn<sup>595</sup> and Met<sup>596</sup>->Leu<sup>596</sup> (695 numbering system)) found in a Swedish FAD family produce approximately five-to-eight-fold more A $\beta$  than cells expressing normal APP (Citron et al. (1992) *Nature*, 360:672-674). The mutation at residue 596 appears to be principally responsible for the increase.

#### V. EXPRESSION VECTORS FOR APP

10 Host cells transfected with a recombinant expression vector that encodes APP also are useful as cells in the screening methods of this invention. A plasmid that carries sequences encoding APP is pCMV695 (Selkoe et al. (1988) *Proc. Natl. Acad. Sci USA* 85:7341-7345).

15 Nucleic acids encoding APP can be obtained by methods known in the art. For example, a nucleic acid encoding an APP can be isolated by polymerase chain reaction of cDNA or genomic DNA from a human brain cDNA library or a human genomic library using primers based on the DNA sequence of APP. PCR methods are described in, for example, U.S. Pat. No. 4,683,195; Mullis et al. (1987) *Cold Spring Harbor Symp. Quant. Biol.* 51:263; and Erlich, ed., *PCR Technology*, (Stockton Press, NY, 1989).

25 Mutant versions of APP, such as the Swedish mutation, can be made by site-specific mutagenesis of other nucleic acids encoding APP, or by random mutagenesis caused by increasing the error rate of PCR of the original polynucleotide with 0.1 mM MnCl<sub>2</sub> and unbalanced nucleotide concentrations.

The construction of expression vectors and the expression of genes in transfected cells involves the use of molecular cloning techniques also well known in the art. Sambrook et al., *Molecular Cloning -- A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, (1989) and *Current Protocols in Molecular Biology*, F.M. Ausubel et al., eds., (Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc.).

35 Nucleic acids used to transfect cells with sequences coding for expression of the polypeptide of interest generally will be in the form of an expression vector that includes

expression control sequences operatively linked to a nucleotide sequence coding for expression of the polypeptide. As used herein, the term nucleotide sequence "coding for expression of" a polypeptide refers to a sequence that, upon transcription and translation of mRNA, produces the polypeptide. As any person skilled in the art recognizes, this includes all degenerate nucleic acid sequences encoding the same amino acid sequence. This can include sequences containing, e.g., introns. As used herein, the term "expression control sequences" refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are "operatively linked" to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus, expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (i.e., ATG) in front of a protein-encoding gene, splicing signals for introns, maintenance of the correct reading frame of that gene to permit proper translation of the mRNA, and stop codons.

The recombinant nucleic acid can be incorporated into an expression vector comprising expression control sequences operatively linked to the recombinant nucleic acid. The expression vector can be adapted for function in prokaryotes or eukaryotes by inclusion of appropriate promoters, replication sequences, markers, etc.

The expression vector can be transfected into a host cell for expression of the recombinant nucleic acid. Host cells can be selected for high levels of expression in order to purify the protein. The host cell can be a prokaryotic or eukaryotic cell selected to study the activity of an enzyme produced by the cell. The cell can be, e.g., a cultured cell or a cell *in vivo*.

Transfected host cells useful in this invention include human kidney 293 cell lines such as K695sw, and K695<sup>7171</sup>, glioma cell lines such as HS695, and neuroblastoma cell lines such as SKN695, described in the Experimental section.

VI. MEASURING A $\beta$ (x- $\geq$ 41)

A $\beta$  peptides can be detected by any method known in the art. Preferably, the method involves an immunoassay employing binding substances specific for the peptides.

5 Optionally, one can detect A $\beta$  peptides by determining their size, e.g., by HPLC or by mass spectrometry.

A. Binding Substances

One step of the screening methods of this invention involves measuring the amount of at least one A $\beta$ (x- $\geq$ 41) peptide, specifically, in a sample. Measuring A $\beta$ (x- $\geq$ 41) peptides specifically means measuring A $\beta$ (x- $\geq$ 41) peptides so as to distinguish that molecule from shorter species of A $\beta$ , i.e., those species whose carboxy-terminus extends no further than amino acid # 40 of A $\beta$ .

15 Specific measurement of A $\beta$ (x- $\geq$ 41) preferably is performed by the use of binding substances that specifically recognize A $\beta$ (x- $\geq$ 41) peptides, e.g., binding substances that recognize amino acids of A $\beta$  beyond amino acid # 40.

Another method of this invention involves screening 20 compounds to determine their ability to alter the production of both A $\beta$ (x- $\geq$ 41) peptides and total A $\beta$  or A $\beta$ (x- $\leq$ 40) peptides. Such methods can involve the use of binding substances that can distinguish A $\beta$ (x- $\leq$ 40) peptides from longer species of A $\beta$ , such as A $\beta$ (x- $\geq$ 41) peptides.

25

B. Immunoassays

The use of immunological detection techniques, i.e., immunoassays employing binding substances, is preferred. Particularly suitable detection techniques include ELISA, 30 Western blotting, radioimmunoassay, and the like. Suitable immunological methods employing a single antibody are also contemplated, for example, radioimmunoassay using an antibody specific for  $\geq$ 41 forms of A $\beta$ , or single antibody ELISA methods. It will be clear that the particular forms of A $\beta$  detected by 35 such methods depend upon the particular binding substances employed. For example, binding substances directed to the junction region may detect A $\beta$ (x- $\geq$ 41) peptides whose amino termini do not extend to amino acid no. 1 of A $\beta$ . Also, binding

substances directed to the carboxy-terminal end of  $A\beta(x-\geq 41)$  may detect peptides ending at amino acids 41, 42 or 43. Therefore, determining the specificity of the binding substances will assist in determining exactly which  $A\beta(x-\geq 41)$  peptides the assay is detecting.

In one embodiment, the method to detect  $A\beta(x-\geq 41)$  peptides is an immunoassay involving two antibodies. One antibody is specific for an epitope containing amino acids beyond number 40 in  $A\beta$ , and another antibody is capable of distinguishing  $A\beta$  and  $A\beta$  fragments from other APP fragments which might be found in the sample. In particular, it has been found that antibodies which are monospecific for the junction region of  $A\beta$  are capable of distinguishing  $A\beta$  from other APP fragments. The junction region of  $A\beta$  is centered at amino acid residues 16 and 17, typically spanning amino acid residues -13 to -28. Such "junction-recognizing" antibodies may be prepared using synthetic peptides having that sequence as an immunogen.

A preferred immunoassay technique is a two-site or "sandwich" assay. This assay involves a capture binding substance, usually bound to a solid phase, and a labelled detection binding substance. In this method,  $A\beta(x-\geq 41)$  peptides are captured from the sample using a first binding substance specific for  $A\beta(x-\geq 41)$  peptides (usually bound to a solid phase). The capture of  $A\beta(x-\geq 41)$  peptides is detected using a labeled second binding substance specific for  $A\beta$ . Labeled binding substances include, for example, those directed to the junction region (amino acids -13 to -28) or binding substances specific for amino-terminal amino acids (1-5 or 1-12).

Particular methods for preparing such antibodies and utilizing such antibodies in an exemplary ELISA are set forth in the Experimental section hereinafter and in related United States patent application 07/965,972, *supra*. A sandwich assay using an antibody against the junction region can be used to specifically measure  $A\beta$  and  $A\beta$  fragments whose amino-terminus begins before amino acid 13 of  $A\beta$ . Such assays do not recognize p3 or p3 fragments, since those peptides begin at amino acid # 17 of  $A\beta$ .

Antibodies specific for  $A\beta(x \geq 41)$ , i.e., which do not cross react with  $A\beta(\leq 40)$ , are particularly useful in the methods of this invention. These antibodies can be made by immunizing animals with synthetic peptides that include amino acids beyond number 40 of  $A\beta$ . For example, the synthetic peptide can include amino acids 33-42. A specific example of the production of such an antibody is provided in the Experimental section.

The particular peptides measured from among the group of all  $A\beta(x \geq 41)$  depends on the particular measuring method used. In the case of using binding substances, such as antibodies, the binding substance can be directed to one or more from among the group of peptides. For example, an antibody raised against amino acids 33-42 of  $A\beta$  that does not cross react with  $A\beta(1-40)$  will bind to  $A\beta(x-42)$ . It also may bind to  $A\beta(x-41)$  and  $A\beta(x-43)$ . According to one embodiment of the invention, the method involves determining the amount of  $A\beta(x \geq 41)$  having at least amino acids 13-41 of  $A\beta$ . These species can be measured using a sandwich assay employing antibodies that recognize the junction region (amino acids 13-26) and antibodies produced by immunization with a hapten having  $A\beta$  amino acids 33-42. Total  $A\beta$  can be measured using a capture antibody to the junction region (e.g., the 266 antibody, described herein) and a reporter antibody that should detect virtually all the  $A\beta$  peptides and  $A\beta$  fragments, e.g., an antibody raised against amino acids 1-12 of  $A\beta$ .

### C. Pulse-Chase Assays

Another method of measuring the amount of  $A\beta(x \geq 41)$  in a sample involves pulse-chase procedures. In these methods, the culture is pulsed with a radioactive label for protein, e.g., a radioactive amino acid such as  $^{35}\text{S}$  methionine. Then the culture is chased without the label. Then the compound is administered to the cells. Then the cells are contacted with a binding substance specific for  $A\beta(x \geq 41)$  and the amount of radioactive label attached to the binding substance is determined.

D. Preparation of Antibodies

Antibodies specific for A $\beta$  can be prepared, e.g., by immunizing an animal with a peptide whose amino acid sequence corresponds with amino acids ~13 to ~28 of A $\beta$ . Antibodies  
5 specific for A $\beta$ (x- $\geq$ 41) can be prepared, e.g., by immunizing an animal with a peptide whose amino acid sequence corresponds with amino acids 33-42 of A $\beta$ . Antibodies specific for A $\beta$ (x-  
10  $\leq$ 40) can be prepared, e.g., by immunizing an animal with a peptide whose amino acid sequence corresponds with amino acids 33-40 or 28-40 of A $\beta$ . Antibodies against the junction region are useful for detecting total A $\beta$ .

Synthetic polypeptide haptens may be produced by the well-known Merrifield solid-phase synthesis technique in which amino acids are sequentially added to a growing chain  
15 (Merrifield (1963) *J. Am. Chem. Soc.* 85:2149-2156). Suitable peptide haptens will usually comprise at least five contiguous residues within A $\beta$  and may include more than six residues. The amino acid sequences may be based on the sequence of A $\beta$  set forth above.

20 Once a sufficient quantity of polypeptide hapten has been obtained, it may be conjugated to a suitable immunogenic carrier, such as serum albumin, keyhole limpet hemocyanin, or other suitable protein carriers, as generally described in Hudson and Hay, *Practical Immunology*, Blackwell Scientific  
25 Publications, Oxford, Chapter 1.3, 1980. An exemplary immunogenic carrier utilized in the examples provided below is  $\alpha$ -CD3 $\epsilon$  antibody (Boehringer-Mannheim, Clone No. 145-2C11).

Antibodies specific for the desired epitope may be produced by *in vitro* or *in vivo* techniques. *In vitro*  
30 techniques involve exposure of lymphocytes to the immunogens, while *in vivo* techniques require the injection of the immunogens into a suitable vertebrate host. Suitable vertebrate hosts are non-human, including mice, rats, rabbits, sheep, goats, and the like. Immunogens are injected into the  
35 animal according to a predetermined schedule, and the animals are periodically bled, with successive bleeds having improved titer and specificity. The injections may be made intramuscularly, intraperitoneally, subcutaneously, or the

like, and an adjuvant, such as incomplete Freund's adjuvant, may be employed.

If desired, monoclonal antibodies can be obtained by preparing immortalized cell lines capable of producing  
5 antibodies having desired specificity. Such immortalized cell lines may be produced in a variety of ways. Conveniently, a small vertebrate, such as a mouse, is hyperimmunized with the desired immunogen by the method just described. The vertebrate is then killed, usually several days after the final  
10 immunization, the spleen cells removed, and the spleen cells immortalized. The manner of immortalization is not critical. Presently, the most common technique is fusion with a myeloma cell fusion partner, as first described by Kohler and Milstein (1975) *Nature* 256:495-497. Other techniques including EBV  
15 transformation, transformation with bare DNA, e.g., oncogenes, retroviruses, etc., or any other method which provides for stable maintenance of the cell line and production of monoclonal antibodies. Specific techniques for preparing monoclonal antibodies are described in *Antibodies: A*  
20 *Laboratory Manual*, Harlow and Lane, eds., Cold Spring Harbor Laboratory, 1988.

In addition to monoclonal antibodies and polyclonal antibodies (antisera), the detection techniques of the present invention will also be able to use antibody fragments, such as  
25 F(ab), Fv, V<sub>L</sub>, V<sub>H</sub>, and other fragments. In the use of polyclonal antibodies, however, it may be necessary to adsorb the anti-sera against the target epitopes in order to produce a monospecific antibody population. It will also be possible to employ recombinantly produced antibodies (immunoglobulins) and  
30 variations thereof as now well described in the patent and scientific literature. See, for example, EPO 8430268.0; EPO 85102665.8; EPO 85305604.2; PCT/GB 85/00392; EPO 85115311.4; PCT/US86/002269; and Japanese application 85239543, the disclosures of which are incorporated herein by reference. It  
35 would also be possible to prepare other recombinant proteins which would mimic the binding specificity of antibodies prepared as just described.

## VII. KITS

This invention also provides kits for performing assays of the invention. The kits include means for detecting specifically  $A\beta(x \geq 41)$  and means for detecting specifically  $A\beta(x \leq 40)$ . The means can include any means known or described above, e.g., binding substances.

In one embodiment, the kit includes a binding substance specific for  $A\beta(x \geq 41)$  (i.e., that does not cross react with  $A\beta(\leq 40)$ ), and a binding substance specific for  $A\beta(\leq 40)$  (i.e., that does not cross react with  $A\beta(x \geq 41)$ ). Such kits are useful, e.g., in pulse-chase assays.

In another embodiment, the kit is useful for immunoassays including two antibodies for each antigen. For example, the kit can further comprise a binding substance specific for the junction region of  $A\beta$ . Such antibodies are useful for the capture or detection of both  $A\beta(x \geq 41)$  and  $A\beta(\leq 40)$ . In one kit useful for a sandwich ELISA, the binding substance specific for the junction region is bound to a solid phase, and the binding substances specific for  $A\beta(x \geq 41)$  and  $A\beta(\leq 40)$  are detectably labeled.

The detectable labels can be any known and used in the art including, e.g., a biotinylation label, a radioactive label, a light scattering label, an enzymatic label, a fluorescent label and the like. When the label is enzymatic, the kit can further comprise a substrate for the enzyme.

## VIII. TEST COMPOUNDS

The test compounds can be any molecule, compound, or other substance which can be added to the cell culture or administered to the test animal without substantially interfering with cell or animal viability. Suitable test compounds may be small molecules (i.e., molecules whose molecular mass is no more than 1000 Daltons), biological polymers, such as polypeptides, polysaccharides, polynucleotides, and the like. The test compounds will typically be administered to the culture medium at a concentration in the range from about 1 nM to 1 mM, usually from about 10  $\mu$ M to 1 mM. The test compounds will typically be

administered at a dosage of from 1 ng/kg to 100 mg/kg, usually from 10  $\mu$ g/kg to 1 mg/kg.

Test compounds which are able to inhibit secretion or production of  $A\beta(x-\geq 41)$  are considered as candidates for further determinations of the ability to block  $\beta$ -amyloid production in animals and humans. Such compounds can be tested in *in vivo* studies, as described below. Inhibition of secretion or production indicates that cleavage of  $A\beta$  between amino acids 42/43 has likely been at least partly blocked, reducing the amount of  $A\beta(x-\geq 41)$  available for forming  $\beta$ -amyloid plaques.

#### IX. IN VIVO SCREENING

Animal models currently are being used to study Alzheimer's disease. (See, e.g., International Patent Application WO 93/14200, U.S. patent application 08/143,697, filed October 27, 1993 (Atty. docket 4.20, allowed), U.S. Patent 5,387,742, and U.S. application 08/486,538, filed June 7, 1995.) These models are useful for screening compounds that alter the production of  $A\beta(x-\geq 41)$  in the assays of this invention for their ability to affect the course of Alzheimer's disease, both to ameliorate and aggravate the condition. Transgenic mammalian models, more particularly, rodent models and in particular murine, hamster and guinea pig models, are suitable for this use.

A preferred non-human transgenic animal is one whose cells harbor a PDAPP construct. A PDAPP construct is a nucleic acid construct that comprises a mammalian promoter operatively linked to a cDNA-genomic DNA hybrid coding for the expression of APP. The cDNA-genomic DNA hybrid contains a cDNA sequence encoding APP770 or a cDNA sequence encoding APP770 with a naturally occurring mutation (e.g., a Hardy mutation or the Swedish mutation) substituted with genomic DNA sequences. The genomic DNA sequences consist of exon 6 and an amount of the adjacent downstream intron sufficient for splicing, the KI and OX-2 coding region and an amount of each of their upstream and downstream introns sufficient for splicing, and exon 9 and an amount of the adjacent upstream intron sufficient for splicing,

substituted into the corresponding region of the cDNA sequence encoding APP770, or the cDNA encoding APP770 with a naturally occurring mutation. The construct is transcribed and differentially spliced in mammalian cells to form mRNA molecules that encode and that are translated into APP695, APP751 and APP770. In certain embodiments, the construct contains a PDGF- $\beta$  promoter operatively linked with a hybrid sequence encoding an APP gene harboring a Hardy mutation (V717F), and the SV40 polyadenylation signal. One version of the PDAPP construct is presented in Example IX.

Another useful non-human animal model harbors a copy of an expressible transgene sequence which encodes the Swedish mutation of APP (asparagine<sup>595</sup>-leucine<sup>596</sup>). The sequence generally is expressed in cells which normally express the naturally-occurring endogenous APP gene (if present). Such transgenes typically comprise a Swedish mutation APP expression cassette, in which a linked promoter and, preferably, an enhancer drive expression of structural sequences encoding a heterologous APP polypeptide comprising the Swedish mutation. A $\beta$  levels can be measured in any body fluid or tissue sample, for example, brain homogenate.

The transgenic animals that are usually produced by introducing the transgene or targeting construct into a fertilized egg or embryonic stem (ES) cell, typically by microinjection, electroporation, lipofection, or biolistics. The transgenic animals express the Swedish mutation APP gene of the transgene (or homologously recombined targeting construct), typically in brain tissue. Preferably, one or both endogenous APP alleles is inactivated and incapable of expressing the wild-type APP.

In all cases, it will be necessary to obtain a control value which is characteristic of the level of A $\beta$ (x- $\geq$ 41) and/or total A $\beta$  or A $\beta$ (x- $\leq$ 40) production in the test animal in the absence of test compound(s). In cases where the animal is sacrificed, it will be necessary to base the value on an average or a typical value from other test animals which have been transgenically modified to express the Swedish mutant of human APP but which have not received the administration of any

test compounds or any other substances expected to affect the level of production of  $A\beta(x-\geq 41)$  and/or total  $A\beta$  or  $A\beta(x-\leq 40)$ . Once such control level is determined, test compounds can be administered to additional test animals, in which deviation  
5 from the average control value would indicate that the test compound had an effect on the  $\gamma$ -secretase activity in the animal. Test substances which are considered positive, *i.e.*, likely to be beneficial in the treatment of Alzheimer's disease or other  $\beta$ -amyloid-related conditions, will be those which are  
10 able to reduce the level of  $A\beta(x-\geq 41)$  production, preferably by at least 20%, more preferably by at least 50%, and most preferably by at least 80%.

The following examples are offered by way of  
15 illustration, not by way of limitation.

## EXPERIMENTAL

### I. ANTIBODY PREPARATION

#### A. Monoclonal Antibodies to the $A\beta$ Junction Region

20 Monoclonal antibodies to the junction region of  $A\beta$  were prepared using a synthetic peptide spanning amino acid residues 13-30, except that AI, amino acids 30 and 31, were substituted with GC (the "junction peptide"). The junction peptide was conjugated to an immunogen ( $\alpha$ -CD3 $\epsilon$  antibody; Clone  
25 No. 145-2C11, Boehringer-Mannheim) using m-maleimidobenzoyl-N-hydroxysuccinimide ester (MHS) according to the manufacturer's (Pierce) instructions.

A/J mice were immunized initially intraperitoneally (IP) with the  $A\beta$  conjugate mixed with complete Freund's  
30 adjuvant. Fourteen days later, the mice were boosted IP with the  $A\beta$  conjugate mixed with phosphate buffered saline (PBS) at 14 day intervals. After six total boosts, the mice were finally boosted intravenously with  $A\beta$  conjugate mixed with incomplete Freund's adjuvant and fused 3 days later. Fusion of  
35 spleen cells with P3.653 myeloma cells was performed as described in Oi and Herzenberg, *Selective Methods in Cellular Immunology*, Mishell and Shigii, Eds., W.H. Freeman and Company, San Francisco, Chapter 17 (1980). Serum titers and initial

screens were performed by the RIA method described below. Several clones were expanded to a 24-well plate and subjected to further analysis as described below. Clones of interest were produced in mouse ascites.

5           The RIA method used to screen serum bleeds and fusion hybridoma supernatants was based upon a method developed by Wang et al. (1977) *J. Immunol. Methods* 18:157-164. Briefly, the supernatant (or serum) was incubated overnight at room temperature on a rotator with <sup>125</sup>I-labeled A $\beta$ <sub>1-28</sub> and Sepharose®  
10 4B beads to which sheep anti-mouse IgG had been coupled via cyanogen bromide. The beads from each well were harvested onto glass fiber filter discs with a cell harvester and washed several times with PBS. The filter discs were then transferred to gamma tubes and the bound radioactivity was counted in a  
15 gamma counter.

          All hybridomas were tested for binding to A $\beta$ <sub>1-28</sub> using the method described above in the initial screen, and then retested 3 days later. A $\beta$ <sub>1-28</sub> positive clones were further characterized for reactivity to <sup>125</sup>I-labeled A $\beta$ <sub>1-16</sub> using  
20 the RIA method described above. No clones were found to bind A $\beta$ <sub>1-16</sub>. In a peptide capture ELISA, all clones were found to react with A $\beta$ <sub>13-28</sub> while no clones reacted with A $\beta$ <sub>17-28</sub>. Therefore, it was determined that all clones had an epitope within the junction region spanning amino acids 16 and 17.

25           Based on results of the above assays, several clones were expanded into 24 well plates. These clones were further characterized by saturation analysis. Supernatants at the 50% titer point (as determined by the RIA method described above) were added to wells containing Sepharose®-sheep anti-mouse IgG  
30 beads, a constant amount of <sup>125</sup>I-labeled A $\beta$ <sub>1-28</sub>, and varying amounts of unlabeled junction peptide or A $\beta$ <sub>17-28</sub>. The concentration of cold peptide for 50% inhibition was determined for each antibody. For the A $\beta$ <sub>17-28</sub>, no inhibition was seen at 100 ng/well for any clones. The 50% inhibition point for  
35 junction peptide ranged from 10-80 ng/well. The clones were also characterized based on reactivity in Western blots. Based on titer point, sensitivity (as determined by the 50% inhibition point), and reactivity on Western blot, several

clones were produced in ascites. Antibodies from hybridoma designated 266 (the "266 antibody") was selected for use as a capture antibody in the assays described below.

Supernatants from wells containing hybridoma cells were screened for antibody with the ability to capture <sup>125</sup>I labeled A $\beta$  1-42 in solution by immunoprecipitation (Notebook 1101).

#### B. 2G3 Production

Antibody 2G3, specific for A $\beta$ (x-40), was produced by injecting female A/J mice intraperitoneally with 100  $\mu$ g immunogen per injection. The immunogen consisted of the peptide NH<sub>2</sub>-Cys-NH-CH<sub>2</sub>-(CH<sub>2</sub>)<sub>5</sub>-CO-GLMVGGVV-COOH (SEQ ID NO:5), coupled to sheep anti-mouse IgG using maleimidohexanoyl-N-hydroxysuccinimide. The immunogen was emulsified with Freund's complete adjuvant for the first immunization, and all subsequent immunizations were with 100  $\mu$ g of immunogen emulsified with Freund's incomplete adjuvant at approximately two week intervals.

Three days before fusion, a mouse was boosted with PBS solutions containing 50  $\mu$ g immunogen intravenously and 50  $\mu$ g intraperitoneally in PBS. The mouse was sacrificed, the spleen was removed, splenocytes were isolated and fused with the SP2/0 mouse myeloma using a modification of the method of Koehler and Milstein.

Supernatants from wells containing hybridoma cells were screened for the ability to produce antibody which recognizes A $\beta$ (1-40) which had been coated onto an ELISA plate. "Positives" were further screened for their ability to capture <sup>125</sup>I A $\beta$ (1-40) in solution by immunoprecipitation.

#### C. Production of 21F12

Antibody 21F12, specific for A $\beta$ (x $\geq$ 41) was produced by immunizing A/J mice intraperitoneally with 100  $\mu$ g of immunogen per injection. The immunogen consists of the synthetic peptide NH<sub>2</sub>-Cys-NH-CH<sub>2</sub>(CH<sub>2</sub>)<sub>5</sub>-CO-GLMVGGVVIA-COOH (SEQ ID NO:4) coupled to sheep anti-mouse IgG using maleimidohexanoyl-N-hydroxysuccinimide (MHS). The immunogen was emulsified with

Freund's complete adjuvant for the first immunization, and all subsequent immunizations were with 100  $\mu\text{g}$  of immunogen emulsified with Freund's incomplete adjuvant at approximately two week intervals.

5 Three days before the fusion, a mouse was injected with 50  $\mu\text{g}$  of immunogen each intravenously and intraperitoneally of immunogen in PBS. Three days post injection, the spleen was removed, splenocytes were isolated and fused with SP2/0 following a modification of the method of  
10 Koehler and Milstein.

D. Specificity of 2G3 and 21F12

The specificities of antibody 2G3 and 21F12 are demonstrated in Figures 1 and 2. In this assay, antibody 2G3  
15 or 21F12 was coated into the wells of an ELISA plate by diluting the purified antibody to a concentration of 10  $\mu\text{g}/\text{ml}$  in Well-coating Buffer (0.01 M  $\text{PO}_4$ , pH 8.5), and pipetting 100  $\mu\text{l}$  of the antibody solution into each well. The solution was left overnight at room temperature and then was removed by  
20 aspiration. The non-specific sites of the well were blocked by the addition of 200  $\mu\text{l}$  0.25% Human Serum albumin in PBS and incubated for at least one hour at room temperature. The blocking solution was removed and the wells were washed one time with wash buffer (Tris buffered Saline, 0.05% Tween 20).

25 Standards containing between 80-20,000 pg/ml of either  $\text{A}\beta(1-40)$  or  $\text{A}\beta(1-42)$  were then prepared by dilution in Specimen Diluent (1 mM  $\text{PO}_4$ , 0.15 M NaCl, pH 7.4, 0.6% Bovine Serum albumin, globulin-free, 0.05% Triton X-405 and 0.05% Thimerosal), and 100  $\mu\text{l}$  of each of these standards were added  
30 to the appropriate wells. The standards were incubated for one hour at room temperature, then aspirated and the wells washed four times with wash buffer.

100  $\mu\text{l}$  of a second antibody (the reporter antibody) was added at a concentration of 0.5  $\mu\text{g}/\text{ml}$  in specimen diluent.  
35 This reporter antibody is biotinylated 3D6 (which recognizes  $\text{A}\beta(1-5)$ ) prepared by the reaction of antibody with NHS-biotin (Pierce). This was allowed to incubate one hour at room temperature, and then washed four times with wash buffer.

To each well, 100  $\mu$ l of a 1/5000 dilution of avidin HRP (Vector Labs) was added and allowed to incubate one hour at room temperature. The wells were washed four times in wash buffer, and 100  $\mu$ l of Slow TMB (Pierce) were added to each well and incubated fifteen minutes. The reaction was stopped by the addition of 25  $\mu$ l of 2 M  $H_2SO_4$  and the plates were read at 450-650 on a Vmax reader (Molecular Devices) (Notebook 1344).

As can be seen in Figure 1, antibody 2G3 reacts strongly with  $A\beta(1-40)$ , but has essentially no cross-reactivity with  $A\beta(1-42)$ . In Figure 2, it is shown that antibody 21F12 similarly has very high specificity, in this case for  $A\beta(1-42)$  over  $A\beta(1-40)$ . At a concentration of 20,000 pg/ml less than 0.4% of cross reactivity is observed.

## II. ELISA ASSAY

### A. Binding of Capture Antibody to Microtiter Wells

A monoclonal antibody against  $A\beta(x \geq 41)$  or  $A\beta(x \leq 40)$  is diluted to a concentration of 10  $\mu$ g/ml in a buffer containing 0.23g/L  $NaH_2PO_4 \cdot H_2O$ , 26.2g/L  $Na_2HPO_4 \cdot 7H_2O$ , 1g/L  $NaN_3$ , pH 8.5. One hundred  $\mu$ l/well of this solution is then dispensed in a 96 well white Dynatech Microlite 2, 96 well flat-bottomed plate. The plates are sealed and incubated overnight at room temperature. Following coating, the remaining solution was aspirated and the non-specific binding sites are blocked with 200  $\mu$ L per well of ( $NaH_2PO_4 \cdot H_2O$ ) 0.2g/L,  $Na_2HPO_4 \cdot 7H_2O$  0.8g/L, human serum albumin (HSA) crystallized and lyophilized 2.5g/L, pH 7.4. These plates are blocked by incubating for 1 hour at room temperature in the blocking solution.

### B. Assay Protocol

The calibrators are prepared from a stock solution of  $A\beta_{1-42}$ , 1 $\mu$ g/ml, in DMSO. In specimen diluent (( $NaH_2PO_4 \cdot H_2O$ ) 0.2g/L,  $Na_2HPO_4 \cdot 7H_2O$  2.16g/L,  $NaN_3$  0.5g/L, bovine serum albumin (BSA) (globulin free) 6g/L, triton x-405 0.5ml/L NaCl 8.5g/L, pH 7.4.), the highest calibrator, 1000 pg/ml (10 $\mu$ l  $A\beta_{1-42}$  stock (1 $\mu$ g/ml DMSO) in 10 ml casein specimen diluent) is prepared. Sequential dilutions are made in specimen diluent to obtain 500, 250, 125, 62.5 and 31.25 pg/ml concentrations of  $A\beta_{1-42}$ .

One hundred  $\mu\text{L}$  per well calibrators or samples are applied to the microtiter plates. The plates are sealed and incubated for 1 hour at room temperature. The plates are then washed three times with washing buffer (NaCl 80 g/L, KCl 3.85 g/L, Tris-HCl 31.75 g/L, tween-20 0.5 ml/L, pH 7.5).

Antibody is diluted in specimen diluent to  $1\mu\text{g/ml}$  and  $100\mu\text{l}$  is added per well. The plate is covered and incubated for 1 hour at room temperature. The plate is washed three times with washing buffer. The alkaline phosphatase affinity purified F(ab')<sub>2</sub> fragment donkey anti-rabbit IgG (H+L) (Jackson) is diluted 1:1000 in specimen diluent. One hundred  $\mu\text{l/well}$  is added. The plate is covered and incubated for 1 hour at room temperature. The plate is washed three times with washing buffer, then  $100\mu\text{l/well}$  of chemiluminescent substrate is added. The chemiluminescent substrate is prepared by diluting the chemiluminescent reagent, AMPPD (Tropix), and an enhancer, emerald green (Tropix), 1:1000 and 1:100 respectively in 1M diethanolemine buffer, pH 10, containing 1 mM MgCl<sub>2</sub> and 0.2% NaN<sub>3</sub>. The plates are sealed and incubated for 10 to 15 minutes at room temperature. Solution is not aspirated. This time may have to be optimized for different antibody lots.

Chemiluminescence is read and expressed as relative chemiluminescence units (CLU) after 15 minutes using a Dynatech ML 1000.

### III. INHIBITION OF APP PROCESSING BY THE MDL 28170 INHIBITOR

We first set out to reproduce the published results of Higaki et al. (1995) *Neuron*, 14:651-659 on the action of the compound MDL 28170 on APP processing, using human kidney 293 cells stably expressing APP<sub>695</sub> with the Swedish FAD mutation (K695sw cells). Our experiments were done using a pulse-chase paradigm: K695sw cells were labeled for 2 hours with 35S-methionine and then chased for 2 hours in the presence of 200  $\mu\text{M}$  MDL 28170. Aliquots of the chase media from treated and untreated cells were subjected to SDS-PAGE. No significant differences in the amounts of the major secreted cellular proteins were detected (Fig. 3, lanes 1, 2), suggesting that

under the conditions of the experiment, MDL 28170 does not interfere with general protein secretion.

We next analyzed the chase media for changes in the amounts of  $\alpha$ - and  $\beta$ -cleaved APP<sub>s</sub>, using antibodies specific for each form. Antibody 1736 specifically immunoprecipitates  $\alpha$ -cleaved APP<sub>s</sub> (Haass et al. (1994) *J. Biol. Chem.* 269:17741-17748; Haass et al. (1995) *Nature Med.* 1:1291-1296). This antibody revealed an increase in  $\alpha$ -APP<sub>s</sub> production upon treatment (Fig. 3, lanes 3, 4), indicating that MDL 28170 does not significantly inhibit  $\alpha$ -secretase.

192sw specifically immunoprecipitates the  $\beta$ -cleaved APP<sub>s</sub> species ending with the Swedish mutant met<sub>596</sub> (Knops et al. (1995) *J. Biol. Chem.* 270:2419-2422; Haass et al. (1995) *Nature Med.* 1:1291-1296). Immunoprecipitation with this antibody showed that MDL 28170 does not significantly inhibit  $\beta$ -secretase activity (Fig. 3, lanes 5, 6).

We next analyzed lysates of the K695sw cells for changes in cellular full-length APP and its C-terminal fragments using antibody C7, directed to the last 20 amino acids of APP (Podlisny et al. (1991) *Am. J. Pathol.* 138:1423-1435). This antibody precipitates N'- and N'/O'- glycosylated full-length APP and its 10 kDa C-terminal fragment (residues 613-695 of APP<sub>695</sub>) that remains membrane bound after  $\alpha$ -secretase cleavage. Upon treatment with MDL 28170, a striking increase in the level of the 10 kDa C-terminal fragment was observed (Fig. 3, lanes 7, 8).

In K695sw cells, the 12 kDa C-terminal fragment (residues 597-695 of APP<sub>695</sub>) which remains membrane bound after  $\beta$ -secretase cleavage cannot be easily resolved and detected by antibody C7 (Citron et al., 1995). We therefore precipitated this fragment using antibody 1282 raised to synthetic A $\beta$ (1-40). This antibody can precipitate the 12 kDa C-terminal but not the 10 kDa fragment, and therefore the faint 12 kDa band is not overshadowed by the much more abundant 10 kDa band. Whereas no 12 kDa fragment was detectable in untreated cells, this band was clearly observed upon treatment with MDL 28170 (Fig. 3, lanes 9, 10).

In summary, no significant inhibition of  $\alpha$ - or  $\beta$ -secretase cleavage, but an increase in both the 10 and 12 kDa C-terminal fragments was observed upon treatment with MDL 28170, strongly supporting the role of this compound as a  $\gamma$ -secretase inhibitor which inhibits the conversion of the 10 and 12 kDa fragments to the p3 and A $\beta$  peptides, respectively.

IV. MDL 28170 INHIBITS THE PRODUCTION OF A $\beta$ (40) AND p3(40) BUT NOT A $\beta$ (42) AND p3(42)

MDL 28170 had previously been shown to inhibit the secretion of A $\beta$  and p3 and therefore had been suggested to inhibit  $\gamma$ -secretase. This inhibition was observed by immunoprecipitating media from treated cells with a polyclonal antibody raised to synthetic A $\beta$ (1-40) (Higaki et al., (1995) *Neuron*, 14:651-659). Since the vast majority of secreted A $\beta$  and p3 peptides end at amino acid 40, this experiment does not distinguish whether only the major  $\gamma$ -secretase cleavage at position 40 is inhibited.

To address this question, we performed pulse-chase experiments on K695sw cells using different doses of MDL 28170, followed by sequential immunoprecipitation of the same media first with 21F12, a monoclonal antibody raised against amino acids 33-42 of A $\beta$  (described above) which specifically precipitates A $\beta$  peptides ending at position 42, and then with antibody 1282 which precipitates all forms of A $\beta$  and p3 (Haass et al., (1992b) *Nature* 359:322-325) (Fig. 4A). Interestingly, 21F12 precipitated not only A $\beta$ , but also p3 peptides, thus demonstrating the existence of secreted p3(42), which had not been described before. Total A $\beta$  and total p3 were strongly and significantly decreased with doses of MDL 28170 > 50  $\mu$ M (e.g., at 200  $\mu$ M  $p < 0.001$ ). In contrast, A $\beta$ (42) and p3(42) showed a bell-shaped dose response curve, with only a small and insignificant decrease at 200  $\mu$ M, the dose used by Higaki et al. (1995) *Neuron*, 14:651-659, and the highest dose tested here. Using MDL 28170 at 200  $\mu$ M, the experiment was repeated four times and the results were quantitated by phosphorimaging (Fig. 4B). These data indicate that under the conditions

described above the differential effect is significant for both  $A\beta$  and p3.

V. DIFFERENTIAL INHIBITION IS ACCOMPLISHED UNDER A NUMBER OF  
5 CONDITIONS

To make sure that the differential effect observed in  $A\beta(40)/A\beta(42)$  and p3(40)/p3(42) precipitations is meaningful, we performed a number of control experiments using the K695sw cells. First we treated K695sw cells in a 2 h pulse 2 h chase  
10 paradigm with 1  $\mu$ M of the phorbol ester PDBu, which has been shown to decrease total  $A\beta$  but increase total p3, probably by diverting  $\beta$ APP substrate from the  $\beta$ -secretase pathway to the  $\alpha$ -secretase route (Buxbaum et al., (1993) "Protein phosphorylation inhibits production of alzheimer amyloid  $\beta/A4$   
15 peptide," *Proc. Natl. Acad. Sci. USA* 90:9195-9198; Hung et al., (1993) "Activation of protein kinase C inhibits cellular production of the amyloid  $\beta$ -protein," *J. Biol. Chem.* 268:22959-22962). This effect should be independent of the subsequent  $\gamma$ -secretase cleavage and thus the 40 and 42 forms of each  
20 metabolite should be equally decreased or increased if the immunoprecipitation paradigm used here works correctly. Indeed, when conditioned media of PDBu-treated cells was precipitated with 21F12, the expected decrease in  $A\beta(42)$  and increase in p3(42) were observed indicating that  $A\beta(42)$   
25 immunoprecipitation signal does reflect changes in the amounts of precipitable material. Subsequent immunoprecipitation with R1282 shows the same effect for total  $A\beta$  and total p3 (Fig. 5A).

The statement that  $A\beta(42)$  and p3(42) are not  
30 decreased by MDL 28170 depends critically on the quality of the 21F12 antibody. To confirm the effects observed with this antibody, two other previously published  $A\beta(42)$ -specific antibodies were used in the pulse chase paradigm with MDL 28170 at 200  $\mu$ M. The monoclonal antibody BC05 has been extensively  
35 used in ELISA assays to detect  $A\beta(42)$  (Asami-Odaka et al., (1995) *Biochemistry* 34:10272-10278; Gravina et al., (1995) *J. Biol. Chem.* 270:7013-7016; Suzuki et al., (1994) *Science* 264:1336-1340).

When media from MDL 28170-treated K695sw cells was precipitated with this antibody, we observed an actual increase in both A $\beta$ (42) and p3(42). The subsequent precipitation with R1282 showed the usual decrease in total A $\beta$  and p3 (Fig. 5B).

5 The polyclonal antibody C42 has also been shown to be specific for A $\beta$ (42) (Saido et al., (1994) Spatial resolution of the primary  $\beta$ -amyloidogenic process induced in postischemic hippocampus. *J. Biol. Chem.* 269:15253-15257). Likewise, this antibody did not show a decrease in A $\beta$ (42) and p3(42) upon  
10 treatment whereas the subsequent precipitation with R1282 showed the usual decrease in total A $\beta$  and p3 (Fig. 5C).

The decrease in A $\beta$ (40) and p3(40) was also found when the monoclonal antibody, 2G3 (described above) specific for the free carboxyl-terminus of A $\beta$ (40) and p3(40) was used to  
15 precipitate first, followed by 21F12 (Fig. 5D). As expected, the differential inhibition of A $\beta$  production by MDL 28170 was also detected when the precipitations were carried out not sequentially (as described above) but in parallel after the standard pulse-chase. That is, aliquots of media from treated  
20 cells and from untreated cells were precipitated with 21F12 for the A $\beta$ 42 forms and other aliquots were precipitated with antibody 1282 for total A $\beta$  and total p3. This parallel precipitation produced the same result as the sequential precipitations described above (Fig. 5E).

25 In summary, three different A $\beta$ (42) end-specific antibodies show that MDL 28170 does not strongly decrease A $\beta$ (42) and p3(42) production whereas a monoclonal antibody to A $\beta$ (40) and p3(40) and different polyclonal antibodies to total A $\beta$  and p3 show a strong decrease. Finally, immunoprecipitation  
30 with 21F12 followed by antibody 1282 again revealed this differential inhibition when the inhibitor (100  $\mu$ M) was applied during a 3 h labeling period instead of in a pulse-chase format (Fig. 5F).

#### 35 VI. DIFFERENTIAL INHIBITION IS OBSERVED IN SEVERAL CELL LINES

To check whether the differential inhibition is specific for K695sw, three additional cell lines were treated in the standard 2 h pulse-2 h chase paradigm, and the

conditioned media were precipitated first with 21F12 and then with antibody 1282. The kidney cell line K695<sub>717I</sub> expresses APP<sub>695</sub> carrying the 717I mutation. This line was chosen because it produces increased levels of A $\beta$ (42) due to the mutation (Suzuki et al., (1994) *Science* 264:1336-1340). At 200  $\mu$ M MDL 28170, no decrease of A $\beta$ (42) and p3(42) was observed, whereas A $\beta$ (40) and p3(40) were substantially reduced. (Fig. 6A). The Chinese Hamster ovary cell line CHO695 transfected with wild-type  $\beta$ APP<sub>695</sub> cDNA was treated with 200  $\mu$ M MDL 28170 and only a slight decrease of A $\beta$ (42) and p3(42) was observed, whereas A $\beta$ (40) and p3(40) were substantially reduced. (Fig. 6B). The human neuroblastoma cell-line SKN695 expressing wild type  $\beta$ APP<sub>695</sub> was treated with 200  $\mu$ M MDL 28170 (Fig. 6C). While A $\beta$ (42) and p3(42) were slightly increased, total A $\beta$  and total p3 were strongly decreased. Thus, differential inhibition of A $\beta$ (42) vs A $\beta$ (40) and p3(42) vs p3(40) production is not only observed in K695sw but also in a cell line with an Alzheimer's disease linked  $\beta$ APP717 missense mutation, in a hamster cell line and in a human neural cell line expressing wild type  $\beta$ APP.

20

## VII. EXPERIMENTAL PROCEDURES

### A. Cell lines

All transfected cell lines described here carry derivatives of pCMV695, a plasmid carrying APP<sub>695</sub> under control of the CMV promoter (Selkoe, (1988) *Proc. Natl. Acad. Sci.* 85:7341-7345) K695sw are human embryonic kidney 293 cells stably transfected with a construct carrying the AD-linked double ("Swedish") mutation K595N/M596L (Citron et al. (1992) *Nature*, 360:672-674); K695<sub>717I</sub> are 293 cells stably transfected with APP<sub>695</sub> carrying the mutation V717I (valine to isoleucine at position 717 in the APP770 numbering system). CHO695 are Chinese hamster ovary cells (CHO) stably transfected with pCMV695 (Oltersdorf (1990) *J. Biol. Chem.* 265:4432-4437) SKN695 are SK-N-SH human neuroblastoma cells stably transfected with

35

B. Pulse-chase experiments and immunoprecipitations

To analyze the effect of MDL 28170 on the processing of APP, cells were grown to confluence in two 10 cm dishes, pulse-labeled with 600  $\mu$ Ci of [<sup>35</sup>S]-methionine in 4 ml of serum-free medium for 2 hours and then chased for 2 hours with 4 ml medium containing 10% fetal bovine serum and the indicated final concentration of MDL 28170 (initially dissolved at 200 mM in DMSO). Control dishes were treated with DMSO alone.

Conditioned media and cell lysates were analyzed by immunoprecipitation, as described (Haass, et al. *Nature* 10 359:322-325). Polyclonal antibody R1736 to residues 595-611 of APP<sub>695</sub>, was used to precipitate  $\alpha$ -APP<sub>s</sub> (Haass, (1994) *J. Biol. Chem.* 269:17741-17748). This antibody recognizes an epitope that is specific for the free COOH-terminus of  $\alpha$ -cleaved APP<sub>s</sub>.  
15 Polyclonal antibody R1282 was generated to synthetic A $\beta$ <sub>1-40</sub> (Haass, et al. (1992) *Nature* 359:322-325). This antibody precipitates total A $\beta$  and p3 (and small, variable amounts of APP<sub>s</sub>) from the media of cultured cells (Haass, et al. (1992) *Nature* 359:322-325). The monoclonal antibody 2G3 was raised to  
20 peptide C(Aminoheptanoic acid)GLMVGGVV (SEQ ID NO:5) and specifically precipitates A $\beta$ (40) and p3(40). Twenty  $\mu$ g of this antibody were used to immunoprecipitate the chase media of 2 dishes. The monoclonal antibody 21F12 was raised to peptide C(Aminoheptanoic acid)GLMVGGVVIA (SEQ ID NO:4) and specifically  
25 precipitates A $\beta$ (42) and p3(42). Twenty  $\mu$ g of this antibody were used to immunoprecipitate the chase media of 2 dishes. The monoclonal antibody BC05 specifically detects A $\beta$ (42) and p3(42) (Suzuki et al., (1994) *Science* 264:1336-1340). The polyclonal antibody C7 against the last 20 residues of the APP  
30 cytoplasmic tail (Podlisny, (1991) *Am. J. Pathol.* 138:1423-1435) precipitates N'- and N' plus O'-glycosylated full-length APP as well as its C-terminal proteolytic fragments. The antibody sw192 (Knops et al. (1995) *J. Biol. Chem.* 270:2419-2422; Haass et al. (1995) *Nature Med.* 1:1291-1296) specifically  
35 precipitates  $\beta$ -cleaved APP<sub>s</sub> carrying the Swedish mutation.

SDS-PAGE of immunoprecipitates of cell extracts or of A $\beta$  from media was carried out on 10-20% Tris-Tricine gels (Novex), whereas APP<sub>s</sub> precipitates were electrophoresed on 10%

SDS-polyacrylamide Tris Glycine gels. All quantitations were performed with a Phosphorimager 400A using Image-QuANT software (Molecular Dynamics). It should be noted the pulse/chase-immunoprecipitation method allows one to assess any changes in  $A\beta$  and p3 simultaneously in the same assay, with each of these peptides being visualized directly in the electrophoretic gel.

#### VIII. HUMAN NEURONS

Human neurons were cultured as previously described (Seubert et al. *Nature* (1992) 359:325-327) except that the cells were seeded into 6-well plates in neuronal medium without fetal bovine serum but supplemented with B27 (Gibco). Cells were cultured for 2-3 weeks in serum free medium prior to use.

PDAPP mouse brain cells from 16 day old fetal cerebral cortex were cultured following the protocol for human neurons except the cells were seeded into 24-well plate clusters in neuronal medium with 5% fetal bovine serum (Sigma) and 5% Chang's supplement (Irvine Scientific). Cells were cultured for 5-7 days prior to being used in experiments.

The procedure for examining the effects of substances on  $A\beta$  production is as follows. Fresh medium is added to the culture wells and then collected after ~ 24 (8-30) hrs. This is the "control" sample from each well that the treated sample will be compared to. Fresh medium, containing the substance to be tested is then added and again harvested after a further ~ 24 hr (8-30) incubation. After collection of this "treated" sample, a cytotoxicity assay is performed on the cells. To perform the cytotoxicity assay, cells are incubated in media containing thiazolyl blue (MTT, Sigma) at 1 mg/ml for 15 minutes. The media are then discarded, and the precipitates are analyzed by solubilization in a buffer containing 50% DMF and 20% SDS. The solubilized dye was quantitated on a Molecular Devices Vmax.

Control and treated samples of culture media are assayed for total  $A\beta$  using a sandwich ELISA consisting of two monoclonal antibodies. The first antibody 266, specific to amino acids 13-28 of  $A\beta$ , is used as a capture antibody (Seubert et al., *Nature*, *supra*). The second antibody, 3D6 which is

specific to amino acids 1-5 of A $\beta$ , was biotinylated and served as a reporter antibody. The 3D6 biotinylation procedure employed the manufacturer's protocol for NHS-biotin (Pierce) labeling of immunoglobulins, except 100 mM sodium bicarbonate, 5 pH 8.5, buffer was used. The 3D6 antibody does not recognize secreted APP or full-length APP but does recognize A $\beta$  species that begin at position 1.

The samples were also assayed for A $\beta$ (42) with an A $\beta$ (42) specific sandwich ELISA that employed the monoclonal 10 antibody 21F12, which was generated against amino acids 33-42 of A $\beta$ , as the capture antibody. This antibody is specific for longer forms of A $\beta$  since it does not cross-react with A $\beta$ (1-40) in ELISA or competitive radioimmunoassay (RIA). Biotinylated 3D6 is also the reporter antibody in this assay.

15 The 266 and 21F12 mAbs were coated at 10  $\mu$ g/ml into 96-well immunoassay plates (Costar) overnight at room temperature. The plates were aspirated and blocked with 0.25% human serum albumin PBS buffer for at least 1 hour at room temperature, then stored desiccated at 4°C until use. The 20 samples and standards were added to the plates and incubated at room temperature for 1.5 hours.

The biotinylated 3D6 was diluted to 0.5  $\mu$ g/ml, and incubated in the wells for 1 hour at room temperature. The plates were washed 3 times with wash buffer (Tris buffered 25 saline, 0.05% Tween 20) between each step of the assay. Streptavidin-alkaline phosphatase (Boehringer Mannheim), diluted 1:1000, was added to the wells for the total A $\beta$  assay, and avidin-HRP (Vector) diluted 1:4000 was added to the wells for the A $\beta$ (42) assay. These conjugates were incubated for 30 1 hour at room temperature. For the total A $\beta$  assay the fluorometric substrate 4-methyl-umbelliferyl phosphate was added to the wells for 30 minutes, then read in a Millipore Cytofluor 2350 fluorometer. The colorimetric substrate, Slow TMB-ELISA (Pierce), was added for the A $\beta$ (42) assay and allowed 35 to react for 15 minutes, after which the enzymatic reaction was stopped with 2N H<sub>2</sub>SO<sub>4</sub>. The plates were read on a Molecular Devices Vmax.

Percent inhibition for both total A $\beta$  and A $\beta$ (42) is defined as:

$$(1 - ((\text{treated}/\text{control}_t) / (\text{untreated}/\text{control}_u))) \times 100\%$$

5 where      treated      = value from treated cells  
            control<sub>t</sub>      = value from the same treated well for the  
                            24 hr period prior to testing  
            untreated    = value from well which received no test  
10                              substance  
            control<sub>u</sub>    = value from the same untreated well for  
                            the 24 hr prior to testing

15             It is optimal to divide the values of the treated and untreated samples by their respective values for the 24 hrs prior to the 24 hr test period, as the act of changing the media alone can effect a 5-10% reduction in A $\beta$  production (comparing the untreated to control<sub>u</sub>).

20             Several compounds were screened for their ability to inhibit both total A $\beta$  and A $\beta$ (42). Results are shown in Figs. 13A-13O.

#### IX. PDAPP CONSTRUCT

25             A cDNA/genomic APP construct containing introns 6, 7 and 8 is prepared by combining APP cDNA encoding exons 1-6 and 9-18 with genomic APP sequences encoding introns 6, 7 and 8, and exons 7 and 8 (see Figs. 8A-8B). In order to create a splicing cassette small enough for convenient insertion in a  
30 pUC vector, two deletions in intronic sequences are made. A deletion is made in intron 6 from position 143 of intron 6 to the *Bam*HI site located upstream of the beginning of exon 7 (1658 bp before the beginning of exon 7). Another deletion is  
35 made in intron 8 from the first *Bam*HI site in intron 8 to a site at 263 bp before the beginning of exon 9. To avoid confusion, these truncated forms of APP introns 6 and 8 are referred to herein as intron  $\Delta$ 6 and  $\Delta$ 8. *Bam*HI sites are engineered at the sites of these deletions, so that they are marked by the presence of *Bam*HI sites. In this construct,  
40 referred to as PDAPP, exons 7 and 8 and intron 7 are intact genomic sequences, except that the unique *Xho*I site in intron 7 is destroyed.

DNA fragments containing the truncated introns are generated as follows: a *Bam*HI site is engineered 143 bp into intron 6 nucleotide by PCR mutagenesis ("Mutagenesis by PCR" in *PCR Technology: Current Innovations* (Griffith and Griffith, eds., CRC Press, 1994) pages 69-83) and another *Bam*HI site is engineered by PCR mutagenesis 263 bp prior to the beginning of exon 9. These sites are engineered into separate APP genomic DNA clones containing the junctions of exon 6 and intron 6, and intron 8 and exon 9, respectively, resulting in modified APP genomic DNA clones.

The entire cassette is assembled in the APP cDNA clone as follows (Figure 9). The 889 bp *Bam*HI to *Xcm*I fragment of APP cDNA containing exons 1 through 5 and part of exon 6 (including nucleotides 1 to 843 of Fig. 10 (SEQ ID NO:2)) is cloned into a vector containing *Bam*HI and *Xho*I sites downstream from the insertion site to make APP770x-oligo-x. APP770x-oligo-x is then cut with *Xcm*I and *Bam*HI. Then two fragments are obtained from the modified APP genomic DNA clone containing the junction of exon 6 and intron 6 described above by cutting with *Xcm*I and *Bam*HI. The resulting 34 bp fragment from the *Xcm*I in exon 6 to the *Xcm*I in intron 6, and 131 bp fragment from the *Xcm*I in intron 6 to the artificially created *Bam*HI site at position 143 bp of intron 6 are ligated into APP770x-oligo-x in a three-way ligation step to make APP 770x-E6oligo-x. The orientation of the fragments are confirmed by sequencing. APP770x-E6oligo-x is then cut with *Bam*HI and *Xho*I. Then the 313 bp *Bam*HI and *Xho*I fragment from the modified APP genomic DNA clone containing the junction of intron 8 and exon 9 is ligated into APP770x-E6oligo-x to make APP770xE6E9x.

APP770xE6E9x is then cut with *Bam*HI and the 6.8 kb *Bam*HI fragment of APP genomic DNA encoding the KPI and OX-2 domains (exons 7 and 8) is inserted at this site. This fragment starts at the *Bam*HI site 1658 bp upstream of the start of exon 7 and extends to the first *Bam*HI site in intron 8. This *Bam*HI fragment is obtained from a lambda phage genomic clone encoding this portion of the APP gene, that was obtained from a Human Placental genomic library in the Lambda FIXII vector obtained from Stratagene. This *Bam*HI fragment

originally contained an *XhoI* site which was destroyed by cutting fill in and relegation. The locations of the deletions are diagramed in Figure 11. This clone, containing exons 1-8 and part of 9, and introns 6, 7 and 8, is termed the "APP  
5 splicing cassette." The APP splicing cassette is cut out with *NruI* and *XhoI* and used to replace the *NruI* to *XhoI* cDNA fragment of APP cDNA bearing a Hardy mutation. This mutant form of APP cDNA is produced by converting the G at nucleotide position 2145 to T by site directed mutagenesis. This changes  
10 the encoded amino acid from Val to Phe. The resulting construct is a combination cDNA/genomic APP "minigene."

Sequencing of the 6.8 kb *BamHI* fragment containing APP exons 7 and 8 derived from the APP genomic clone used to generate this construct showed that intron 7 is 2.6 kb long,  
15 and that the first *BamHI* site in intron 8, the upstream site of the deletion in intron 8 engineered into the APP minigene construct, is 2329 bp downstream from the end of exon 8. This does not coincide with the restriction map of the APP gene published by Yoshikai et al. (1990) and Yoshikai et al. (1991).  
20 Comparison of their map to our sequence indicates that Yoshikai et al. switched the order of two *EcoRI* fragments in their restriction mapping. The 1.60 kb *EcoRI* fragment containing exon 8 is actually upstream of the 1.48 kb *EcoRI* fragment and the 1.48 kb *EcoRI* fragment Yoshikai et al. mapped into intron 7  
25 is actually in intron 8. We have confirmed this location for the *EcoRI* fragment containing exon 8 by sizing of PCR generated fragments from human DNA.

This APP minigene is operatively linked to the PDGF- $\beta$  promoter to provide expression of the APP cDNA/genomic  
30 construct in mammalian cells. The PDGF  $\beta$ -chain 5' flanking sequence is inserted upstream of the *NruI* site at the beginning of the APP minigene. This fragment includes 1.3 kb upstream of the transcription initiation site, where the PDGF- $\beta$  promoter resides, and approximately 70 bp of 5' untranslated region,  
35 ending at the *AurII* site (Higgins et al. (1994)). The late SV40 polyadenylation signal, carried on a 240 bp *BamHI* to *BclI* fragment, is added downstream of the APP minigene. This construct, combining the PDGF- $\beta$  promoter, the APP splicing

cassette, a Hardy mutation, and the SV40 polyadenylation signal is referred to as PDAPP (Figure 12).

The present invention provides a novel screening  
5 method for determining whether a compound alters the production  
of  $A\beta(x-\geq 41)$  and/or  $A\beta(x-\leq 40)$  or total  $A\beta$ . While specific  
examples have been provided, the above description is  
illustrative and not restrictive. Many variations of the  
invention will become apparent to those of skill in the art  
10 upon review of this specification. The scope of the invention  
should, therefore, be determined not with reference to the  
above description, but instead should be determined with  
reference to the appended claims along with their full scope of  
equivalents.

15 All publications and patent documents cited in this  
application are incorporated by reference in their entirety for  
all purposes to the same extent as if each individual  
publication or patent document were so individually denoted.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: CITRON, MARTIN  
SELKOE, DENNIS J.  
SEUBERT, PETER A.  
SCHENK, DALE
- (ii) TITLE OF INVENTION: SCREENING COMPOUNDS FOR THE ABILITY TO  
ALTER THE PRODUCTION OF AMYLOID-BETA PEPTIDE (X-241)
- (iii) NUMBER OF SEQUENCES: 5
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: TOWNSEND & TOWNSEND & CREW LLP
  - (B) STREET: TWO EMBARCADERO CENTER, 8TH FLOOR
  - (C) CITY: SAN FRANCISCO
  - (D) STATE: CALIFORNIA
  - (E) COUNTRY: U.S.A.
  - (F) ZIP: 94111-3834
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: PCT
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: STORELLA ESQ., JOHN R.
  - (B) REGISTRATION NUMBER: 32,944
  - (C) REFERENCE/DOCKET NUMBER: 15270-000650PC
- (viii) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (415) 326-2400
  - (B) TELEFAX: (415) 576-0300

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 43 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
 

Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln	Lys
1					5				10					15	
Leu	Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile	Ile
			20					25					30		

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr  
 35 40

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2310 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2310
- (D) OTHER INFORMATION: /function= "coding region for APP770"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATG CTG CCC GGT TTG GCA CTG CTC CTG CTG GCC GCC TGG ACG GCT CGG	48
Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg	
1 5 10 15	
GCG CTG GAG GTA CCC ACT GAT GGT AAT GCT GGC CTG CTG GCT GAA CCC	96
Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro	
20 25 30	
CAG ATT GCC ATG TTC TGT GGC AGA CTG AAC ATG CAC ATG AAT GTC CAG	144
Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn Val Gln	
35 40 45	
AAT GGG AAG TGG GAT TCA GAT CCA TCA GGG ACC AAA ACC TGC ATT GAT	192
Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys Thr Cys Ile Asp	
50 55 60	
ACC AAG GAA GGC ATC CTG CAG TAT TGC CAA GAA GTC TAC CCT GAA CTG	240
Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu Val Tyr Pro Glu Leu	
65 70 75 80	
CAG ATC ACC AAT GTG GTA GAA GCC AAC CAA CCA GTG ACC ATC CAG AAC	288
Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr Ile Gln Asn	
85 90 95	
TGG TGC AAG CGG GGC CGC AAG CAG TGC AAG ACC CAT CCC CAC TTT GTG	336
Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe Val	
100 105 110	
ATT CCC TAC CGC TGC TTA GTT GGT GAG TTT GTA AGT GAT GCC CTT CTC	384
Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu	
115 120 125	
GTT CCT GAC AAG TGC AAA TTC TTA CAC CAG GAG AGG ATG GAT GTT TGC	432
Val Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys	
130 135 140	
GAA ACT CAT CTT CAC TGG CAC ACC GTC GCC AAA GAG ACA TGC AGT GAG	480
Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu	
145 150 155 160	

AAG	AGT	ACC	AAC	TTG	CAT	GAC	TAC	GGC	ATG	TTG	CTG	CCC	TGC	GGA	ATT	528
Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile	
				165					170					175		
GAC	AAG	TTC	CGA	GGG	GTA	GAG	TTT	GTG	TGT	TGC	CCA	CTG	GCT	GAA	GAA	576
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu	
			180					185					190			
AGT	GAC	AAT	GTG	GAT	TCT	GCT	GAT	GCG	GAG	GAG	GAT	GAC	TCG	GAT	GTC	624
Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val	
		195					200					205				
TGG	TGG	GGC	GGA	GCA	GAC	ACA	GAC	TAT	GCA	GAT	GGG	AGT	GAA	GAC	AAA	672
Trp	Trp	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys	
	210					215					220					
GTA	GTA	GAA	GTA	GCA	GAG	GAG	GAA	GAA	GTG	GCT	GAG	GTG	GAA	GAA	GAA	720
Val	Val	Glu	Val	Ala	Glu	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu	
	225				230				235						240	
GAA	GCC	GAT	GAT	GAC	GAG	GAC	GAT	GAG	GAT	GGT	GAT	GAG	GTA	GAG	GAA	768
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu	
				245					250					255		
GAG	GCT	GAG	GAA	CCC	TAC	GAA	GAA	GCC	ACA	GAG	AGA	ACC	ACC	AGC	ATT	816
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile	
			260					265					270			
GCC	ACC	ACC	ACC	ACC	ACC	ACC	ACA	GAG	TCT	GTG	GAA	GAG	GTG	GTT	CGA	864
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg	
		275					280						285			
GAG	GTG	TGC	TCT	GAA	CAA	GCC	GAG	ACG	GGG	CCG	TGC	CGA	GCA	ATG	ATC	912
Glu	Val	Cys	Ser	Glu	Gln	Ala	Glu	Thr	Gly	Pro	Cys	Arg	Ala	Met	Ile	
	290					295					300					
TCC	CGC	TGG	TAC	TTT	GAT	GTG	ACT	GAA	GGG	AAG	TGT	GCC	CCA	TTC	TTT	960
Ser	Arg	Trp	Tyr	Phe	Asp	Val	Thr	Glu	Gly	Lys	Cys	Ala	Pro	Phe	Phe	
	305				310					315					320	
TAC	GGC	GGA	TGT	GGC	GGC	AAC	CGG	AAC	AAC	TTT	GAC	ACA	GAA	GAG	TAC	1008
Tyr	Gly	Gly	Cys	Gly	Gly	Asn	Arg	Asn	Asn	Phe	Asp	Thr	Glu	Glu	Tyr	
			325					330						335		
TGC	ATG	GCC	GTG	TGT	GGC	AGC	GCC	ATG	TCC	CAA	AGT	TTA	CTC	AAG	ACT	1056
Cys	Met	Ala	Val	Cys	Gly	Ser	Ala	Met	Ser	Gln	Ser	Leu	Leu	Lys	Thr	
			340					345					350			
ACC	CAG	GAA	CCT	CTT	GCC	CGA	GAT	CCT	GTT	AAA	CTT	CCT	ACA	ACA	GCA	1104
Thr	Gln	Glu	Pro	Leu	Ala	Arg	Asp	Pro	Val	Lys	Leu	Pro	Thr	Thr	Ala	
		355					360					365				
GCC	AGT	ACC	CCT	GAT	GCC	GTT	GAC	AAG	TAT	CTC	GAG	ACA	CCT	GGG	GAT	1152
Ala	Ser	Thr	Pro	Asp	Ala	Val	Asp	Lys	Tyr	Leu	Glu	Thr	Pro	Gly	Asp	
	370					375					380					
GAG	AAT	GAA	CAT	GCC	CAT	TTC	CAG	AAA	GCC	AAA	GAG	AGG	CTT	GAG	GCC	1200
Glu	Asn	Glu	His	Ala	His	Phe	Gln	Lys	Ala	Lys	Glu	Arg	Leu	Glu	Ala	
	385				390					395					400	
AAG	CAC	CGA	GAG	AGA	ATG	TCC	CAG	GTC	ATG	AGA	GAA	TGG	GAA	GAG	GCA	1248
Lys	His	Arg	Glu	Arg	Met	Ser	Gln	Val	Met	Arg	Glu	Trp	Glu	Glu	Ala	
			405					410						415		
GAA	CGT	CAA	GCA	AAG	AAC	TTG	CCT	AAA	GCT	GAT	AAG	AAG	GCA	GTT	ATC	1296
Glu	Arg	Gln	Ala	Lys	Asn	Leu	Pro	Lys	Ala	Asp	Lys	Lys	Ala	Val	Ile	
			420					425					430			

CAG CAT TTC CAG GAG AAA GTG GAA TCT TTG GAA CAG GAA GCA GCC AAC Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn 435 440 445	1344
GAG AGA CAG CAG CTG GTG GAG ACA CAC ATG GCC AGA GTG GAA GCC ATG Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met 450 455 460	1392
CTC AAT GAC CGC CGC CGC CTG GCC CTG GAG AAC TAC ATC ACC GCT CTG Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu 465 470 475 480	1440
CAG GCT GTT CCT CCT CGG CCT CGT CAC GTG TTC AAT ATG CTA AAG AAG Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys 485 490 495	1488
TAT GTC CGC GCA GAA CAG AAG GAC AGA CAG CAC ACC CTA AAG CAT TTC Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe 500 505 510	1536
GAG CAT GTG CGC ATG GTG GAT CCC AAG AAA GCC GCT CAG ATC CGG TCC Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser 515 520 525	1584
CAG GTT ATG ACA CAC CTC CGT GTG ATT TAT GAG CGC ATG AAT CAG TCT Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser 530 535 540	1632
CTC TCC CTG CTC TAC AAC GTG CCT GCA GTG GCC GAG GAG ATT CAG GAT Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp 545 550 555 560	1680
GAA GTT GAT GAG CTG CTT CAG AAA GAG CAA AAC TAT TCA GAT GAC GTC Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val 565 570 575	1728
TTG GCC AAC ATG ATT AGT GAA CCA AGG ATC AGT TAC GGA AAC GAT GCT Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala 580 585 590	1776
CTC ATG CCA TCT TTG ACC GAA ACG AAA ACC ACC GTG GAG CTC CTT CCC Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro 595 600 605	1824
GTG AAT GGA GAG TTC AGC CTG GAC GAT CTC CAG CCG TGG CAT TCT TTT Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe 610 615 620	1872
GGG GCT GAC TCT GTG CCA GCC AAC ACA GAA AAC GAA GTT GAG CCT GTT Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val 625 630 635 640	1920
GAT GCC CGC CCT GCT GCC GAC CGA GGA CTG ACC ACT CGA CCA GGT TCT Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser 645 650 655	1968
GGG TTG ACA AAT ATC AAG ACG GAG GAG ATC TCT GAA GTG AAG ATG GAT Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp 660 665 670	2016
GCA GAA TTC CGA CAT GAC TCA GGA TAT GAA GTT CAT CAT CAA AAA TTG Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu 675 680 685	2064
GTG TTC TTT GCA GAA GAT GTG GGT TCA AAC AAA GGT GCA ATC ATT GGA Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly 690 700	2112

51

CTC	ATG	GTG	GGC	GGT	GTT	GTC	ATA	GCG	ACA	GTG	ATC	GTC	ATC	ACC	TTG	2160
Leu	Met	Val	Gly	Gly	Val	Val	Ile	Ala	Thr	Val	Ile	Val	Ile	Thr	Leu	
705					710					715					720	
GTG	ATG	CTG	AAG	AAG	AAA	CAG	TAC	ACA	TCC	ATT	CAT	CAT	GGT	GTG	GTG	2208
Val	Met	Leu	Lys	Lys	Lys	Gln	Tyr	Thr	Ser	Ile	His	His	Gly	Val	Val	
			725						730					735		
GAG	GTT	GAC	GCC	GCT	GTC	ACC	CCA	GAG	GAG	CGC	CAC	CTG	TCC	AAG	ATG	2256
Glu	Val	Asp	Ala	Ala	Val	Thr	Pro	Glu	Glu	Arg	His	Leu	Ser	Lys	Met	
			740					745						750		
CAG	CAG	AAC	GGC	TAC	GAA	AAT	CCA	ACC	TAC	AAG	TTC	TTT	GAG	CAG	ATG	2304
Gln	Gln	Asn	Gly	Tyr	Glu	Asn	Pro	Thr	Tyr	Lys	Phe	Phe	Glu	Gln	Met	
		755					760						765			
CAG	AAC															2310
Gln	Asn															
	770															

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 770 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met	Leu	Pro	Gly	Leu	Ala	Leu	Leu	Leu	Leu	Ala	Ala	Trp	Thr	Ala	Arg	
1				5					10					15		
Ala	Leu	Glu	Val	Pro	Thr	Asp	Gly	Asn	Ala	Gly	Leu	Leu	Ala	Glu	Pro	
			20					25						30		
Gln	Ile	Ala	Met	Phe	Cys	Gly	Arg	Leu	Asn	Met	His	Met	Asn	Val	Gln	
		35					40					45				
Asn	Gly	Lys	Trp	Asp	Ser	Asp	Pro	Ser	Gly	Thr	Lys	Thr	Cys	Ile	Asp	
	50					55						60				
Thr	Lys	Glu	Gly	Ile	Leu	Gln	Tyr	Cys	Gln	Glu	Val	Tyr	Pro	Glu	Leu	
65					70					75					80	
Gln	Ile	Thr	Asn	Val	Val	Glu	Ala	Asn	Gln	Pro	Val	Thr	Ile	Gln	Asn	
				85					90					95		
Trp	Cys	Lys	Arg	Gly	Arg	Lys	Gln	Cys	Lys	Thr	His	Pro	His	Phe	Val	
			100					105						110		
Ile	Pro	Tyr	Arg	Cys	Leu	Val	Gly	Glu	Phe	Val	Ser	Asp	Ala	Leu	Leu	
		115					120					125				
Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	Arg	Met	Asp	Val	Cys	
		130				135						140				
Glu	Thr	His	Leu	His	Trp	His	Thr	Val	Ala	Lys	Glu	Thr	Cys	Ser	Glu	
145					150					155					160	
Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile	
				165					170					175		
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu	
			180					185						190		

Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp Ser Asp Val  
 195 200 205

Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys  
 210 215 220

Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val Glu Glu Glu  
 225 230 235 240

Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu  
 245 250 255

Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile  
 260 265 270

Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg  
 275 280 285

Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile  
 290 295 300

Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe  
 305 310 315 320

Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr  
 325 330 335

Cys Met Ala Val Cys Gly Ser Ala Met Ser Gln Ser Leu Leu Lys Thr  
 340 345 350

Thr Gln Glu Pro Leu Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala  
 355 360 365

Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp  
 370 375 380

Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala  
 385 390 395 400

Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu Ala  
 405 410 415

Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile  
 420 425 430

Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn  
 435 440 445

Glu Arg Gln Gln Leu Val Glu Thr His Met Ala Arg Val Glu Ala Met  
 450 455 460

Leu Asn Asp Arg Arg Arg Leu Ala Leu Glu Asn Tyr Ile Thr Ala Leu  
 465 470 475 480

Gln Ala Val Pro Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys  
 485 490 495

Tyr Val Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe  
 500 505 510

Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser  
 515 520 525

Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln Ser  
 530 535 540

Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu Ile Gln Asp  
 545 550 555 560  
 Glu Val Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Asp Val  
 565 570 575  
 Leu Ala Asn Met Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala  
 580 585 590  
 Leu Met Pro Ser Leu Thr Glu Thr Lys Thr Thr Val Glu Leu Leu Pro  
 595 600 605  
 Val Asn Gly Glu Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe  
 610 615 620  
 Gly Ala Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val  
 625 630 635 640  
 Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser  
 645 650 655  
 Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys Met Asp  
 660 665 670  
 Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu  
 675 680 685  
 Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly  
 690 695 700  
 Leu Met Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu  
 705 710 715 720  
 Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val  
 725 730 735  
 Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys Met  
 740 745 750  
 Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe Glu Gln Met  
 755 760 765  
 Gln Asn  
 770

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 2
- (D) OTHER INFORMATION: /note= "Xaa = NH - CH-2 - (CH-2)-5  
 - CO in an amine linkage between amino acid Cys in position 1  
 and amino acid Gly in position 3"



## WHAT IS CLAIMED IS:

- 1           1.    A method for determining whether a compound  
2 alters the amount of at least one  $A\beta(x-z41)$  peptide produced by  
3 a cell, comprising the steps of:  
4                administering the compound to a culture  
5 comprising the cell;  
6                measuring the amount of the  $A\beta(x-z41)$  peptide,  
7 specifically, in a sample from the culture; and  
8                determining whether the measured amount is  
9 different than the amount expected in a sample from a culture  
10 comprising the cell to which no compound has been administered;  
11                whereby a difference between the measured amount  
12 and the expected amount indicates that the compound alters the  
13 amount of an  $A\beta(x-z41)$  peptide produced by the cell.
  
- 1           2.    The method of claim 1 wherein the amount of the  
2  $A\beta(x-z41)$  peptide is measured by immunoassay.
  
- 1           3.    The method of claim 2 wherein the immunoassay is  
2 a sandwich immunoassay using a capture binding substance bound  
3 to a solid phase and a labeled detection binding substance.
  
- 1           4.    The method of claim 3 wherein the capture  
2 binding substance is specific for  $A\beta(x-z41)$  peptides.
  
- 3           5.    The method of claim 4 wherein the binding  
4 substance has the specificity of a binding substance raised  
5 against peptide  $NH_2-Cys-NH-CH_2(CH_2)_5-CO-GLMVGGVVIA-COOH$  (SEQ ID  
6 NO:4).
  
- 7           6.    The method of claim 4 wherein the labeled  
8 detection binding substance is specific for an epitope within  
9 the junction region of  $A\beta$ .
  
- 1           7.    The method of claim 6 wherein the labeled  
2 detection binding substance has the specificity of a binding  
3 substance raised against the junction peptide of  $A\beta$ .

1           8.    The method of claim 4 wherein the labeled  
2 detection binding substance is specific for an A $\beta$  peptide whose  
3 amino-terminal amino acid is amino acid no. 1 of A $\beta$ .

1           9.    The method of claim 3 wherein the capture  
2 antibody is specific for an epitope within the junction region  
3 of A $\beta$  and the labeled detection antibody is specific for A $\beta$ (x-  
4  $\geq$ 41) peptides.

1           10. The method of claim 3 wherein the culture  
2 comprises primary human neurons or primary neurons from a  
3 transgenic mouse harboring a PDAPP construct.

1           11. The method of claim 10 wherein the PDAPP  
2 construct contains the mutation V717F.

1           12. The method of claim 2 wherein the step of  
2 measuring the amount of the A $\beta$ (x- $\geq$ 41) peptide, specifically, in  
3 a sample from the culture comprises:

4                   pulsing the culture with a radioactive label for  
5 protein;

6                   chasing the culture without a radioactive label;  
7                   administering the compound to the cell during  
8 the chase period;

9                   contacting a sample from the culture with a  
10 binding substance specific for A $\beta$ (x- $\geq$ 41) peptides; and

11                   determining the amount of radioactive label  
12 attached to the binding substance.

1           13. The method of claim 1 wherein the culture  
2 comprises primary human neurons or primary neurons from a  
3 transgenic mouse harboring the PDAPP construct.

1           14. The method of claim 13 wherein the PDAPP  
2 construct contains the mutation V717F.

3           15. The method of claim 1 wherein the culture  
4 comprises a 293 human kidney cell line, a human neuroglioma

5 cell line, a human HeLa cell line, a primary endothelial cell  
6 line, a primary human fibroblast line, a primary lymphoblast  
7 line, human mixed brain cells, or a Chinese hamster ovary (CHO)  
8 cell line.

1 16. The method of claim 1 wherein the cell is a host  
2 cell transfected with a recombinant expression vector encoding  
3 a human APP.

1 17. The method of claim 16 wherein the human APP  
2 possesses a Hardy mutation.

1 18. The method of claim 1 wherein the cell  
2 overproduces  $A\beta(x-\geq 41)$  peptides.

1 19. The method of claim 1 wherein the sample is  
2 medium conditioned by the cell in culture.

1 20. The method of claim 1 further comprising the  
2 step of determining whether the compound is toxic to the cell.

1 21. A method for determining whether a compound  
2 alters the amount of at least one  $A\beta(x-\geq 41)$  peptide produced by  
3 a cell and alters the amount of either total  $A\beta$  or at least one  
4  $A\beta(x-\leq 40)$  peptide produced by the cell comprising:  
5 administering the compound to a culture  
6 comprising the cell;  
7 measuring the amount of the  $A\beta(x-\geq 41)$  peptide,  
8 specifically, in a sample from the culture;  
9 measuring the amount of total  $A\beta$  or the  $A\beta(x-$   
10  $\leq 40)$  peptide, specifically, in a sample from the culture; and  
11 determining whether the measured amounts are  
12 different than the amounts expected in a sample from a culture  
13 comprising the cell to which no compound has been administered;  
14 whereby differences between the measured amounts  
15 and the expected amounts indicate that the compound alters the  
16 amount of the  $A\beta(x-\geq 41)$  peptide by a cell and/or the amount of  
17 total  $A\beta$  or the  $A\beta(x-\leq 40)$  peptide by the cell.

1           22. The method of claim 21 wherein the amount of the  
2 A $\beta$ (x- $\geq$ 41) peptide and the amount of total A $\beta$  or the A $\beta$ (x- $\leq$ 40)  
3 peptide are measured by immunoassay.

1           23. The method of claim 22 wherein the immunoassay  
2 is a sandwich immunoassay comprising capture binding substances  
3 bound to a solid phase and labeled detection binding  
4 substances.

1           24. The method of claim 23 wherein the capture  
2 binding substance for measuring the amount of the A $\beta$ (x- $\geq$ 41)  
3 peptides are specific for A $\beta$ (x- $\geq$ 41) peptides.

1           25. The method of claim 24 wherein the binding  
2 substance specific for A $\beta$ (x- $\geq$ 41) peptides has the specificity  
3 of a binding substance raised against peptide NH<sub>2</sub>-Cys-NH-CH<sub>2</sub>-  
4 (CH<sub>2</sub>)<sub>5</sub>-CO-GLMVGGVVIA-COOH (SEQ ID NO:4).

1           26. The method of claim 24 wherein the labeled  
2 detection binding substance for measuring the amount of A $\beta$ (x-  
3  $\geq$ 41) peptides is specific for an epitope within the junction  
4 region of A $\beta$  or is specific for an A $\beta$  peptide whose amino-  
5 terminal amino acid is amino acid no. 1 of A $\beta$ .

1           27. The method of claim 23 wherein the capture  
2 binding substance for measuring the amount of total A $\beta$  is  
3 specific for an epitope within the junction region of A $\beta$  and  
4 the capture binding substance for measuring the amount of the  
5 A $\beta$ (x- $\leq$ 40) peptides is specific for A $\beta$ (x- $\leq$ 40) peptides.

1           28. The method of claim 27 wherein the binding  
2 substance specific for an epitope within the junction region of  
3 A $\beta$  has the specificity of a binding substance raised against  
4 the junction peptide of A $\beta$ , and the binding substance specific  
5 for A $\beta$ (x- $\leq$ 40) peptides has the specificity of a binding  
6 substance raised against the peptide NH<sub>2</sub>-Cys-NH-CH<sub>2</sub>-(CH<sub>2</sub>)<sub>5</sub>-CO-  
7 GLMVGGVV-COOH (SEQ ID NO:5).

1           29. The method of claim 27 wherein the labeled  
2 detection binding substance for measuring the amount of A $\beta$ (x-  
3  $\leq$ 40) peptides has the specificity of a binding substance raised  
4 against the junction peptide, and the binding substance for  
5 measuring the amount of total A $\beta$  has the specificity of a  
6 binding substance raised against a peptide whose amino acid  
7 sequence is amino acids within 1-5 of A $\beta$  or amino acids 17-24  
8 of A $\beta$ .

1           30. The method of claim 23 wherein the capture  
2 binding substance for measuring the amount of at least one of  
3 A $\beta$ (x- $\geq$ 41) peptide, total A $\beta$  or A $\beta$ (x- $\leq$ 40) peptide is specific  
4 for an epitope within the junction region of A $\beta$ .

1           31. The method of claim 23 wherein the culture  
2 comprises primary human neurons or primary neurons from a  
3 transgenic mouse harboring the PDAPP construct.

1           32. The method of claim 22 wherein the step of  
2 measuring the amount of the A $\beta$ (x- $\geq$ 41) peptide, total A $\beta$  or the  
3 A $\beta$ (x- $\leq$ 40) peptide in a sample from the culture comprises,  
4 before administration of the compound:  
5                   pulsing the culture with a radioactive label for  
6 protein;  
7                   chasing the culture without a radioactive label;  
8                   administering the compound to the cell during  
9 the chase period;  
10                  contacting a sample from the culture with a  
11 binding substance specific for at least one A $\beta$ (x- $\geq$ 41) peptide;  
12                  contacting a sample from the culture with a  
13 binding substance specific for total A $\beta$  or at least one A $\beta$ (x-  
14  $\leq$ 40) peptide; and  
15                  determining the amount of radioactive label  
16 attached to the binding substances.

1           33. The method of claim 23 wherein the culture  
2 comprises primary human neurons or primary neurons from a  
3 transgenic mouse harboring the PDAPP construct.

1           34. The method of claim 22 wherein the culture  
2 comprises a 293 human kidney cell line, a human neuroglioma  
3 cell line, a human HeLa cell line, a primary endothelial cell  
4 line, a primary human fibroblast line, a primary lymphoblast  
5 line, human mixed brain cells, or a Chinese hamster ovary (CHO)  
6 cell line.

1           35. The method of claim 22 wherein the cell is a  
2 host cell transfected with a recombinant expression vector  
3 encoding a human APP.

1           36. The method of claim 35 wherein the human APP  
2 carries a Hardy mutation.

1           37. The method of claim 22 wherein the cell  
2 overproduces  $A\beta(x-\geq 41)$  peptides.

1           38. The method of claim 22 wherein the sample is  
2 medium conditioned by the cell in culture.

1           39. The method of claim 22 further comprising the  
2 step of determining whether the compound is toxic to the cell.

1           40. A kit for specifically detecting at least one  
2  $A\beta(x-\geq 41)$  peptide and at least one  $A\beta(x-\leq 40)$  peptide in a  
3 sample comprising:

4                   a binding substance specific for at least one  
5  $A\beta(x-\geq 41)$  peptide; and

6                   a binding substance specific for at least one  
7  $A\beta(x-\leq 40)$  peptide.

1           41. The kit of claim 40 wherein the binding  
2 substance specific for  $A\beta(x-\geq 41)$  peptides has the specificity  
3 of a binding substance raised against peptide  $NH_2$ -Cys-NH- $CH_2$ -  
4  $(CH_2)_5$ -CO-GLMVGGVVIA-COOH (SEQ ID NO:4); and the binding  
5 substance specific for  $A\beta(x-\leq 40)$  peptides has the specificity  
6 of a binding substance raised against the peptide  $NH_2$ -Cys-NH-  
7  $CH_2$ - $(CH_2)_5$ -CO-GLMVGGVV-COOH (SEQ ID NO:5).

1           42. A kit for specifically detecting at least one  
2  $A\beta(x-\geq 41)$  peptide and either total  $A\beta$  or at least one  $A\beta(x-\leq 40)$   
3 peptide in a sample in a sandwich immunoassay comprising:

4           a) at least two different binding substances for  
5 measuring the amount of  $A\beta(x-\geq 41)$  peptide; and

6           b) at least two different binding substances for  
7 measuring the amount of total  $A\beta$  or  $A\beta(x-\leq 40)$  peptides.

1           43. The kit of claim 42 wherein one of the binding  
2 substances for measuring the amount of the  $A\beta(x-\geq 41)$  peptides  
3 is a capture binding substance specific for  $A\beta(x-\geq 41)$  peptides  
4 bound to a solid phase.

1           44. The kit of claim 43 wherein the binding  
2 substance specific for  $A\beta(x-\geq 41)$  peptides has the specificity  
3 of a binding substance raised against peptide  $NH_2$ -Cys-NH- $CH_2$ -  
4  $(CH_2)_5$ -CO-GLMVGGVIVIA-COOH (SEQ ID NO:4).

1           45. The kit of claim 42 wherein one of the binding  
2 substances for measuring the amount of  $A\beta(x-\geq 41)$  peptides is a  
3 labeled detection binding substance specific for an epitope  
4 within the junction region of  $A\beta$ .

1           46. The kit of claim 42 wherein one of the binding  
2 substances for measuring the amount of total  $A\beta$  is a capture  
3 binding substance specific for an epitope within the junction  
4 region of  $A\beta$  bound to a solid phase and one of the binding  
5 substances for measuring the amount of the  $A\beta(x-\leq 40)$  peptides  
6 is a capture binding substance specific for  $A\beta(x-\leq 40)$  peptides  
7 bound to a solid phase.

1           47. The kit of claim 46 wherein the binding  
2 substance specific for an epitope within the junction region of  
3  $A\beta$  has the specificity of a binding substance raised against  
4 the junction peptide of  $A\beta$ , and the binding substance specific  
5 for  $A\beta(x-\leq 40)$  peptides has the specificity of a binding

6 substance raised against the peptide <sup>62</sup>NH<sub>2</sub>-Cys-NH-CH<sub>2</sub>-(CH<sub>2</sub>)<sub>5</sub>-CO-  
7 GLMVGGVV-COOH (SEQ ID NO:5).

1 48. The kit of claim 45 wherein the labeled  
2 detection binding substance for measuring the amount of A $\beta$ (x-  
3  $\leq$ 40) peptides has the specificity of a binding substance raised  
4 against the junction peptide, and the binding substance for  
5 measuring the amount of total A $\beta$  has the specificity of a  
6 binding substance raised against a peptide whose amino acid  
7 sequence is amino acids within 1-5 of A $\beta$  or amino acids 17-24  
8 of A $\beta$ .

1 49. The kit of claim 42 wherein the capture binding  
2 substance for measuring the amount of at least one of A $\beta$ (x- $\geq$ 41)  
3 peptide, total A $\beta$  or A $\beta$ (x- $\leq$ 40) peptide is specific for an  
4 epitope within the junction region of A $\beta$ .

1 50. The kit of claim 45 wherein the detectable label  
2 is a biotinylation label, a radioactive label, a light  
3 scattering label, an enzymatic label or a fluorescent label.

1 51. The kit of claim 48 wherein the detectable label  
2 is a biotinylation label, a radioactive label, a light  
3 scattering label, an enzymatic label or a fluorescent label.

1 52. A method for determining whether a compound  
2 alters the amount of at least one A $\beta$ (x- $\geq$ 41) peptide produced by  
3 a non-human mammal and alters the amount of either total A $\beta$  or  
4 at least one A $\beta$ (x- $\leq$ 40) peptide produced by the non-human mammal  
5 comprising:

6 measuring a first amount of the A $\beta$ (x- $\geq$ 41) peptide in  
7 a sample from a non-human animal used as a model of Alzheimer's  
8 disease;

9 measuring a first amount of total A $\beta$  or the A $\beta$ (x- $\leq$ 40)  
10 peptide in a sample from the non-human animal;

11 administering the compound to the non-human animal;

12 measuring a second amount of the A $\beta$ (x- $\geq$ 41) peptide in  
13 a sample from the non-human animal;

14 measuring a second amount of total A $\beta$  or the A $\beta$ (x-  
15  $\leq 40$ ) peptide in a sample from the non-human animal; and  
16 comparing the first amounts with the second amounts,  
17 whereby the comparison indicates whether the compound  
18 increases, decreases, or leaves unchanged the amount of the  
19 A $\beta$ (x- $\geq 41$ ) peptide and increases, decreases, or leaves unchanged  
20 the amount of the A $\beta$ (x- $\leq 40$ ) peptide.

1 53. The method of claim 52 wherein the non-human  
2 animal is a rodent.

1 54. The method of claim 53 wherein the rodent is a  
2 mouse.

1 55. The method of claim 52 wherein the non-human  
2 animal harbors a copy of an expressible transgene sequence  
3 which a Hardy mutation.

1 56. The method of claim 52 wherein the non-human  
1 animal is transformed to express the Swedish mutation of human  
2  $\beta$ -amyloid precursor protein (APP).

1 57. The method of claim 52 wherein the non-human  
2 animal is a transgenic animal harboring a PDAPP construct.

1 58. The method of claim 57 wherein the animal is a  
2 mouse.

STANDARD CURVES OF AB 1-40 AND  
AB 1-42 WITH 2G3 AS A CAPTURE ANTIBODY




Figure 1

STANDARD CURVES OF AB 1-40 VS AB1-42  
USING 21F12 AS A CAPTURE ANTIBODY




Figure 2

3/20




Fig 3

4/20





Fig 4




Fig 5

6/20




Fig 6

7/20

Fig 7





FIG. 8



9/20





Figure 9

genomic fragment from phage library

Xho1 deleted

10/20

FIG. 10A

- (2) INFORMATION FOR SEQ ID NO:5:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 2310 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: double
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: NO
  - (iv) ANTI-SENSE: NO
  - (ix) FEATURE:
    - (A) NAME/KEY: CDS
    - (B) LOCATION: 1-2310
    - (D) OTHER INFORMATION: /function= "coding region for APP770."
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATG	CTG	CCC	GGT	TTG	GCA	CTG	CTC	CTG	CTG	GCC	GCC	TGG	ACG	GCT	CGG	48
Met	Leu	Pro	Gly	Leu	Ala	Leu	Leu	Leu	Leu	Ala	Ala	Trp	Thr	Ala	Arg	
1				5					10					15		
GCG	CTG	GAG	GTA	CCC	ACT	GAT	GGT	AAT	GCT	GGC	CTG	CTG	GCT	GAA	CCC	96
Ala	Leu	Glu	Val	Pro	Thr	Asp	Gly	Asn	Ala	Gly	Leu	Leu	Ala	Glu	Pro	
			20					25					30			
CAG	ATT	GCC	ATG	TTC	TGT	GGC	AGA	CTG	AAC	ATG	CAC	ATG	AAT	GTC	CAG	144
Gln	Ile	Ala	Met	Phe	Cys	Gly	Arg	Leu	Asn	Met	His	Met	Asn	Val	Gln	
		35				40						45				
AAT	GGG	AAG	TGG	GAT	TCA	GAT	CCA	TCA	GGG	ACC	AAA	ACC	TGC	ATT	GAT	192
Asn	Gly	Lys	Trp	Asp	Ser	Asp	Pro	Ser	Gly	Thr	Lys	Thr	Cys	Ile	Asp	
	50					55					60					
ACC	AAG	GAA	GGC	ATC	CTG	CAG	TAT	TGC	CAA	GAA	GTC	TAC	CCT	GAA	CTG	240

11/20

FIG. 10B

Thr 65	Lys	Glu	Gly	Ile	Leu	Gln	Tyr	Cys	Gln	Glu	Val	Tyr	Pro	Glu	Leu		
					70					75					80		
CAG	ATC	ACC	AAT	GTG	GTA	GAA	GCC	AAC	CAA	CCA	GTG	ACC	ATC	CAG	AAC		288
Gln	Ile	Thr	Asn	Val	Val	Glu	Ala	Asn	Gln	Pro	Val	Thr	Ile	Gln	Asn		
				85					90					95			
TGG	TGC	AAG	CGG	GGC	CGC	AAG	CAG	TGC	AAG	ACC	CAT	CCC	CAC	TTT	GTG		336
Trp	Cys	Lys	Arg	Gly	Arg	Lys	Gln	Cys	Lys	Thr	His	Pro	His	Phe	Val		
			100					105					110				
ATT	CCC	TAC	CGC	TGC	TTA	GTT	GGT	GAG	TTT	GTA	AGT	GAT	GCC	CTT	CTC		384
Ile	Pro	Tyr	Arg	Cys	Leu	Val	Gly	Glu	Phe	Val	Ser	Asp	Ala	Leu	Leu		
		115					120					125					
GTT	CCT	GAC	AAG	TGC	AAA	TTC	TTA	CAC	CAG	GAG	AGG	ATG	GAT	GTT	TGC		432
Val	Pro	Asp	Lys	Cys	Lys	Phe	Leu	His	Gln	Glu	Arg	Met	Asp	Val	Cys		
	130					135					140						
GAA	ACT	CAT	CTT	CAC	TGG	CAC	ACC	GTC	GCC	AAA	GAG	ACA	TGC	AGT	GAG		480
Glu	Thr	His	Leu	His	Trp	His	Thr	Val	Ala	Lys	Glu	Thr	Cys	Ser	Glu		
	145				150					155					160		
AAG	AGT	ACC	AAC	TTG	CAT	GAC	TAC	GGC	ATG	TTG	CTG	CCC	TGC	GGA	ATT		528
Lys	Ser	Thr	Asn	Leu	His	Asp	Tyr	Gly	Met	Leu	Leu	Pro	Cys	Gly	Ile		
			165					170						175			
GAC	AAG	TTC	CGA	GGG	GTA	GAG	TTT	GTG	TGT	TGC	CCA	CTG	GCT	GAA	GAA		576
Asp	Lys	Phe	Arg	Gly	Val	Glu	Phe	Val	Cys	Cys	Pro	Leu	Ala	Glu	Glu		
			180					185					190				
AGT	GAC	AAT	GTG	GAT	TCT	GCT	GAT	GCG	GAG	GAG	GAT	GAC	TCG	GAT	GTC		624
Ser	Asp	Asn	Val	Asp	Ser	Ala	Asp	Ala	Glu	Glu	Asp	Asp	Ser	Asp	Val		
		195					200					205					
TGG	TGG	GGC	GGA	GCA	GAC	ACA	GAC	TAT	GCA	GAT	GGG	AGT	GAA	GAC	AAA		672
Trp	Trp	Gly	Gly	Ala	Asp	Thr	Asp	Tyr	Ala	Asp	Gly	Ser	Glu	Asp	Lys		
	210					215					220						
GTA	GTA	GAA	GTA	GCA	GAG	GAG	GAA	GAA	GTG	GCT	GAG	GTG	GAA	GAA	GAA		720
Val	Val	Glu	Val	Ala	Glu	Glu	Glu	Glu	Val	Ala	Glu	Val	Glu	Glu	Glu		
				230					235						240		
GAA	GCC	GAT	GAT	GAC	GAG	GAC	GAT	GAG	GAT	GGT	GAT	GAG	GTA	GAG	GAA		768
Glu	Ala	Asp	Asp	Asp	Glu	Asp	Asp	Glu	Asp	Gly	Asp	Glu	Val	Glu	Glu		
				245					250					255			
GAG	GCT	GAG	GAA	CCC	TAC	GAA	GAA	GCC	ACA	GAG	AGA	ACC	ACC	AGC	ATT		816
Glu	Ala	Glu	Glu	Pro	Tyr	Glu	Glu	Ala	Thr	Glu	Arg	Thr	Thr	Ser	Ile		
			260					265					270				
GCC	ACC	ACC	ACC	ACC	ACC	ACC	ACA	GAG	TCT	GTG	GAA	GAG	GTG	GTT	CGA		864
Ala	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Glu	Ser	Val	Glu	Glu	Val	Val	Arg		
							280					285					
GAG	GTG	TGC	TCT	GAA	CAA	GCC	GAG	ACG	GGG	CCG	TGC	CGA	GCA	ATG	ATC		912
Glu	Val	Cys	Ser	Glu	Gln	Ala	Glu	Thr	Gly	Pro	Cys	Arg	Ala	Met	Ile		
	290					295					300						
TCC	CGC	TGG	TAC	TTT	GAT	GTG	ACT	GAA	GGG	AAG	TGT	GCC	CCA	TTC	TTT		960
Ser	Arg	Trp	Tyr	Phe	Asp	Val	Thr	Glu	Gly	Lys	Cys	Ala	Pro	Phe	Phe		
					310					315					320		

12/20

FIG. 10C

TAC Tyr	GGC Gly	GGA Gly	TGT Cys	GGC Gly	GGC Gly	AAC Asn	CGG Arg	AAC Asn	AAC Asn	TTT Phe	GAC Asp	ACA Thr	GAA Glu	GAG Glu	TAC Tyr	1008
			325					330					335			
TGC Cys	ATG Met	GCC Ala	GTG Val	TGT Cys	GGC Gly	AGC Ser	GCC Ala	ATG Met	TCC Ser	CAA Gln	AGT Ser	TTA Leu	CTC Leu	AAG Lys	ACT Thr	1056
			340					345					350			
ACC Thr	CAG Gln	GAA Glu	CCT Pro	CTT Leu	GCC Ala	CGA Arg	GAT Asp	CCT Pro	GTT Val	AAA Lys	CTT Leu	CCT Pro	ACA Thr	ACA Thr	GCA Ala	1104
		355					360					365				
GCC Ala	AGT Ser	ACC Thr	CCT Pro	GAT Asp	GCC Ala	GTT Val	GAC Asp	AAG Lys	TAT Tyr	CTC Leu	GAG Glu	ACA Thr	CCT Pro	GGG Gly	GAT Asp	1152
	370					375					380					
GAG Glu	AAT Asn	GAA Glu	CAT His	GCC Ala	CAT His	TTC Phe	CAG Gln	AAA Lys	GCC Ala	AAA Lys	GAG Glu	AGG Arg	CTT Leu	GAG Glu	GCC Ala	1200
385					390					395					400	
AAG Lys	CAC His	CGA Arg	GAG Glu	AGA Arg	ATG Met	TCC Ser	CAG Gln	GTC Val	ATG Met	AGA Arg	GAA Glu	TGG Trp	GAA Glu	GAG Glu	GCA Ala	1248
				405					410					415		
GAA Glu	CGT Arg	CAA Gln	GCA Ala	AAG Lys	AAC Asn	TTG Leu	CCT Pro	AAA Lys	GCT Ala	GAT Asp	AAG Lys	AAG Lys	GCA Ala	GTT Val	ATC Ile	1296
			420					425					430			
CAG Gln	CAT His	TTC Phe	CAG Gln	GAG Glu	AAA Lys	GTG Val	GAA Glu	TCT Ser	TTG Leu	GAA Glu	CAG Gln	GAA Glu	GCA Ala	GCC Ala	AAC Asn	1344
		435					440						445			
GAG Glu	AGA Arg	CAG Gln	CAG Gln	CTG Leu	GTG Val	GAG Glu	ACA Thr	CAC His	ATG Met	GCC Ala	AGA Arg	GTG Val	GAA Glu	GCC Ala	ATG Met	1392
	450					455					460					
CTC Leu	AAT Asn	GAC Asp	CGC Arg	CGC Arg	CGC Arg	CTG Leu	GCC Ala	CTG Leu	GAG Glu	AAC Asn	TAC Tyr	ATC Ile	ACC Thr	GCT Ala	CTG Leu	1440
465				470						475				480		
CAG Gln	GCT Ala	GTT Val	CCT Pro	CCT Pro	CGG Arg	CCT Pro	CGT Arg	CAC His	GTG Val	TTC Phe	AAT Asn	ATG Met	CTA Leu	AAG Lys	AAG Lys	1488
				485					490					495		
TAT Tyr	GTC Val	CGC Arg	GCA Ala	GAA Glu	CAG Gln	AAG Lys	GAC Asp	AGA Arg	CAG Gln	CAC His	ACC Thr	CTA Leu	AAG Lys	CAT His	TTC Phe	1536
			500				505						510			
GAG Glu	CAT His	GTG Val	CGC Arg	ATG Met	GTG Val	GAT Asp	CCC Pro	AAG Lys	AAA Lys	GCC Ala	GCT Ala	CAG Gln	ATC Ile	CGG Arg	TCC Ser	1584
		515					520						525			
CAG Gln	GTT Val	ATG Met	ACA Thr	CAC His	CTC Leu	CGT Arg	GTG Val	ATT Ile	TAT Tyr	GAG Glu	CGC Arg	ATG Met	AAT Asn	CAG Gln	TCT Ser	1632
	530					535					540					
CTC Leu	TCC Ser	CTG Leu	CTC Leu	TAC Tyr	AAC Asn	GTG Val	CCT Pro	GCA Ala	GTG Val	GCC Ala	GAG Glu	GAG Glu	ATT Ile	CAG Gln	GAT Asp	1680
545					550					555					560	
GAA Glu	GTT Val	GAT Asp	GAG Glu	CTG Leu	CTT Leu	CAG Gln	AAA Lys	GAG Glu	CAA Gln	AAC Asn	TAT Tyr	TCA Ser	GAT Asp	GAC Asp	GTC Val	1728


13/20

FIG 10D

				565				570				575				
TTG	GCC	AAC	ATG	ATT	AGT	GAA	CCA	AGG	ATC	AGT	TAC	GGA	AAC	GAT	GCT	1776
Leu	Ala	Asn	Met	Ile	Ser	Glu	Pro	Arg	Ile	Ser	Tyr	Gly	Asn	Asp	Ala	
				580					585					590		
CTC	ATG	CCA	TCT	TTG	ACC	GAA	ACG	AAA	ACC	ACC	GTG	GAG	CTC	CTT	CCC	1824
Leu	Met	Pro	Ser	Leu	Thr	Glu	Thr	Lys	Thr	Thr	Val	Glu	Leu	Leu	Pro	
				595					600					605		
GTG	AAT	GGA	GAG	TTC	AGC	CTG	GAC	GAT	CTC	CAG	CCG	TGG	CAT	TCT	TTT	1872
Val	Asn	Gly	Glu	Phe	Ser	Leu	Asp	Asp	Leu	Gln	Pro	Trp	His	Ser	Phe	
				610					615					620		
GGG	GCT	GAC	TCT	GTG	CCA	GCC	AAC	ACA	GAA	AAC	GAA	GTT	GAG	CCT	GTT	1920
Gly	Ala	Asp	Ser	Val	Pro	Ala	Asn	Thr	Glu	Asn	Glu	Val	Glu	Pro	Val	
				625					630					635	640	
GAT	GCC	CGC	CCT	GCT	GCC	GAC	CGA	GGA	CTG	ACC	ACT	CGA	CCA	GGT	TCT	1968
Asp	Ala	Arg	Pro	Ala	Ala	Asp	Arg	Gly	Leu	Thr	Thr	Arg	Pro	Gly	Ser	
				645					650					655		
GGG	TTG	ACA	AAT	ATC	AAG	ACG	GAG	GAG	ATC	TCT	GAA	GTG	AAG	ATG	GAT	2016
Gly	Leu	Thr	Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser	Glu	Val	Lys	Met	Asp	
				660					665					670		
GCA	GAA	TTC	CGA	CAT	GAC	TCA	GGA	TAT	GAA	GTT	CAT	CAT	CAA	AAA	TTG	2064
Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln	Lys	Leu	
				675					680					685		
GTG	TTC	TTT	GCA	GAA	GAT	GTG	GGT	TCA	AAC	AAA	GGT	GCA	ATC	ATT	GGA	2112
Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile	Ile	Gly	
				690					695					700		
CTC	ATG	GTG	GGC	GGT	GTT	GTC	ATA	GCG	ACA	GTG	ATC	GTC	ATC	ACC	TTG	2160
Leu	Met	Val	Gly	Gly	Val	Val	Ile	Ala	Thr	Val	Ile	Val	Ile	Thr	Leu	
				705					710					715	720	
GTG	ATG	CTG	AAG	AAG	AAA	CAG	TAC	ACA	TCC	ATT	CAT	CAT	GGT	GTG	GTG	2208
Val	Met	Leu	Lys	Lys	Lys	Gln	Tyr	Thr	Ser	Ile	His	His	Gly	Val	Val	
				725					730					735		
GAG	GTT	GAC	GCC	GCT	GTC	ACC	CCA	GAG	GAG	CGC	CAC	CTG	TCC	AAG	ATG	2256
Glu	Val	Asp	Ala	Ala	Val	Thr	Pro	Glu	Glu	Arg	His	Leu	Ser	Lys	Met	
				740					745					750		
CAG	CAG	AAC	GGC	TAC	GAA	AAT	CCA	ACC	TAC	AAG	TTC	TTT	GAG	CAG	ATG	2304
Gln	Gln	Asn	Gly	Tyr	Glu	Asn	Pro	Thr	Tyr	Lys	Phe	Phe	Glu	Gln	Met	
				755					760					765		
CAG	AAC															2310
Gln	Asn															
																770

Note: distances are not done to scale

Numbers indicate distances in base pairs



a, b - sites of mutagenesis where BamHI sites were engineered for deletion


B = location of Bam HI sites

X = xhoI, (x) XhoI site destroyed

R = Eco RI

Intron 7 was expanded by 4 bp when the XhoI site was destroyed

Figure 12



PDAPP vector map

16/20

FIG. 13A




FIG. 13B





FIG. 13C



\* THESE PDAPP CULTURES WERE GROWING IN FBS

17/20

FIG. 13D




FIG. 13E





FIG. 13F



\* THESE PDAPP CULTURES WERE GROWN IN 9% FBS

18/20

FIG. 13G




FIG. 13H





FIG. 13I



\* THESE PDAPP CULTURES WERE GROWN IN 2% FBS

19/20

FIG. 13J




FIG. 13K





FIG. 13L



\* THESE PDAPP CULTURES WERE GROWING IN 96 WELL PLATES

FIG. 13M




FIG. 13N





FIG. 13O



THESE PDAPP CULTURES WERE GROWN IN 9% FBS

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/10601

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 G01N33/68 G01N33/50				
According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b>				
Minimum documentation searched (classification system followed by classification symbols) IPC 6 G01N				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	WO 91 04339 A (CALIFORNIA BIOTECHNOLOGY INCORPORATED) 4 April 1991 see claims 1,10-14; example 5 ---	1-4		
A	WO 94 01772 A (THE CHILDREN'S MEDICAL CENTER CORPORATION) 20 January 1994 see claim 1 ---	1-58		
A	WO 93 16101 A (ATHENA NEUROSCIENCES INCORPORATED & ELI LILLY AND COMPANY) 19 August 1993 see claim 1 ---	1-58		
A	WO 94 10569 A (D.B. SCHENK ET AL.) 11 May 1994 see claim 1 -----	1-58		
<input type="checkbox"/> Further documents are listed in the continuation of box C.				
<input checked="" type="checkbox"/> Patent family members are listed in annex.				
° Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;">                     "A" document defining the general state of the art which is not considered to be of particular relevance                      "E" earlier document but published on or after the international filing date                      "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)                      "O" document referring to an oral disclosure, use, exhibition or other means                      "P" document published prior to the international filing date but later than the priority date claimed                 </td> <td style="width: 50%; border: none; vertical-align: top;">                     "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention                      "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone                      "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.                      "&amp;" document member of the same patent family                 </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family			
Date of the actual completion of the international search  <p style="text-align: center; font-size: 1.2em;">19 November 1997</p>		Date of mailing of the international search report  <p style="text-align: center; font-size: 1.2em;">27/11/1997</p>		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  <p style="text-align: center; font-size: 1.2em;">Van Bohemen, C</p>		

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/10601

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9104339 A	04-04-91	AU 641434 B	23-09-93
		AU 6431190 A	18-04-91
		CA 2065404 A	19-03-91
		EP 0493470 A	08-07-92
		JP 5502368 T	28-04-93
		US 5221607 A	22-06-93
-----			
WO 9401772 A	20-01-94	NONE	
-----			
WO 9316101 A	19-08-93	US 5538845 A	23-07-96
		AU 3585293 A	03-09-93
-----			
WO 9410569 A	11-05-94	AU 4844493 A	24-05-94
		CA 2105903 A	27-04-94
		EP 0667959 A	23-08-95
		JP 8502587 T	19-03-96
		US 5593846 A	14-01-97
-----			